Diodes (DIOD) Q3 Earnings Lag Estimates, Revenues Down Y/Y
- Diodes' (DIOD) third-quarter 2023 results reflect challenging macroeconomic conditions and weaker demand.
- 11/09/2023
|
Diodes Incorporated (DIOD) Q3 2023 Earnings Call Transcript
- Diodes Incorporated (NASDAQ:DIOD ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Leanne Sievers - President, Shelton Group, Investor Relations Keh-Shew Lu - Chairman, President & Chief Executive Officer Gary Yu - Chief Operating Officer Brett Whitmire - Chief Financial Officer Emily Yang - Senior Vice President, Worldwide Sales & Marketing Conference Call Participants William Stein - Truist Securities David Williams - Benchmark Gary Mobley - Wells Fargo Securities Tyler Bomba - Baird Operator Good afternoon, and welcome to Diodes Incorporated Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-on mode.
- 11/08/2023
|
Diodes Incorporated to Announce Third Quarter 2023 Financial Results on November 8
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Wednesday, November 8, 2023, at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its third quarter 2023 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gary Yu, Chief Operating Officer. The Company inten.
- 10/18/2023
|
New Strong Sell Stocks for October 6th
- DIOD, CWK and D have been added to the Zacks Rank #5 (Strong Sell) List on October 6, 2023.
- 10/06/2023
|
Diodes (DIOD) Q2 Earnings Beat Estimates
- Diodes (DIOD) came out with quarterly earnings of $1.59 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $1.90 per share a year ago.
- 08/08/2023
|
Two Value Tech Stocks Trading Near a Breakout Level
- In today's ever-evolving investment landscape, technology has emerged as a clear standout, surpassing the broader market with its remarkable performance year-to-date. YTD, popular technology ETF Invesco QQQ NASDAQ: QQQ is up 44%, while the SPDR S&P 500 ETF NYSE: SPY is up 19.48%, respectively.
- 07/31/2023
|
Diodes Incorporated to Announce Second Quarter 2023 Financial Results on August 8
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Tuesday, August 8, 2023, at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its second quarter 2023 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gary Yu, Chief Operating Officer. The Company intends.
- 07/18/2023
|
Diodes (DIOD) Expands Portfolio With Low-Voltage Hall Latches
- Diodes (DIOD) expands its portfolio with the launch of a new line of low-voltage, high-sensitivity Hall-effect latches - AH171xQ series.
- 07/12/2023
|
The 7 Best Semiconductor Stocks to Buy in July
- As the lifeblood of the technology sector ecosystem, acquiring the best semiconductor stocks in July almost represents a no-brainer. To be sure, every segment of the capital markets carries downside risk.
- 07/06/2023
|
Diodes' (DIOD) New Solutions Strengthen Automotive Footprint
- Diodes (DIOD) launches new solutions ??? AS333Q, Silicon Carbide (SiC) MOSFETs and the ZXCT21xQ family of high-precision current shunt monitors?
- 06/30/2023
|
7 Chip Stocks to Buy if You Missed Out on NVDA
- While everybody seemingly loves chip manufacturer Nvidia (NASDAQ: NVDA ), its overheated nature organically yields a discussion about alternative chip stocks to NVDA. Don't get me wrong, Nvidia is an awesome company.
- 06/21/2023
|
Civitas and Mueller Can Boast High Profit, Low Debt
- Two of the badges of corporate success are high profits and low debt.
- 06/19/2023
|
The 7 Best Mid-Cap Stocks to Buy Now for Big Yields
- From one angle, the concept of the best mid-cap stocks to buy might appear rather ho-hum if not downright uninteresting. For example, investors seeking maximum return potential (in exchange for risk) may target micro-capitalization plays.
- 06/05/2023
|
7 Undervalued Tech Stocks for Smart Investors to Consider Using the Piotroski F-Score
- With groundbreaking innovations emerging in burgeoning sectors such as artificial intelligence and cloud computing, investors have a fertile landscape for investments in technology-oriented enterprises.
- 05/30/2023
|
3 Safe Stocks to Buy to Sleep Like a Baby
- When the Covid-19 crisis faded, Americans finally looked forward to a broader recovery, which on paper doesn't necessarily incentivize the best sleep-well-at-night stocks. However, lingering headwinds – such as stubbornly high inflation – along with fresh negative catalysts (most notably a worsening geopolitical backdrop) require a rethink of reliable enterprises.
- 05/29/2023
|
Diodes Incorporated (DIOD) Q1 2023 Earnings Call Transcript
- Diodes Incorporated (NASDAQ:DIOD ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Leanne Sievers – Shelton Group Investor relations Keh-Shew Lu – Chairman, President and Chief Executive Officer Brett Whitmire – Chief Financial Officer Emily Yang – Senior Vice President-Worldwide Sales and Marketing Gary Yu – Chief Operating Officer Gurmeet Dhaliwal – Director-Investor Relations Conference Call Participants Matt Ramsay – Cowen Gary Mobley – Wells Fargo Securities David Williams – Benchmark Tristan Gerra – Baird William Stein – Truist Securities Operator Good afternoon everyone, and welcome to Diodes Incorporated First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 05/09/2023
|
Diodes Inc.: Today's Best Nearby Semiconductor Stock Cap-Gain Prospect
- Diodes Inc.: Today's Best Nearby Semiconductor Stock Cap-Gain Prospect.
- 04/27/2023
|
Diodes Incorporated to Announce First Quarter 2023 Financial Results on May 9
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Tuesday, May 9, 2023 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its first quarter 2023 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gary Yu, Chief Operating Officer.
- 04/18/2023
|
7 Solid Technology Stocks to Buy for Consistent Returns
- While boring but safe industries look quite compelling amid the rancorous noise of the banking sector fallout and the ever-present concern of high inflation, investors will to take some risks may want to consider solid technology stocks to buy for consistent or credible returns. As leading innovators, these enterprises may eventually find traction, thus leading to upside returns.
- 04/02/2023
|
7 Value Stocks Worth Buying at These 52-Week Highs
- With the market still digesting the tremors of the banking sector fallout, investors may want to consider compelling value stocks to buy, even those trading near their 52-week highs. True, investors often wax poetic about buying low and selling high.
- 03/22/2023
|
These Semiconductor Stocks Jumped While Others Fell On Earnings News
- Fourth-quarter earnings season for semiconductor stocks continues to be a mixed bag. Rambus stock fell while Skyworks stock rose Tuesday.
- 02/07/2023
|
Diodes Incorporated (DIOD) Q4 2022 Earnings Call Transcript
- Diodes Incorporated (NASDAQ:DIOD ) Q4 2022 Earnings Conference Call February 6, 2023 5:00 PM ET Company Participants Leanne Sievers - President, Shelton Group, Investor Relations Dr. Keh-Shew Lu - Chairman, President and CEO Brett Whitmire - Chief Financial Officer Emily Yang - Senior Vice President, Worldwide Sales and Marketing Gary Yu - Senior Vice President, Business Group Gurmeet Dhaliwal - Director, Investor Relations Conference Call Participants William Stein - Truist Joshua Buchalter - Cowen Operator Good afternoon. And welcome to Diodes Incorporated Fourth Quarter and Fiscal 2020 Financial Results Conference Call.
- 02/06/2023
|
Diodes (DIOD) Beats Q4 Earnings and Revenue Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 5.49% and 1.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/06/2023
|
Diodes Incorporated to Announce Fourth Quarter and Fiscal 2022 Financial Results on February 6, 2023
- PLANO, Texas--( BUSINESS WIRE )--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Monday, February 6, 2023 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its fourth quarter and fiscal 2022 financial results.
- 01/17/2023
|
Diodes Inc.: Up Against Resistance
- Diodes Inc. stock has soared higher in recent weeks thanks to a strong report, but it is probably due for a correction with resistance in the way. DIOD is doing fine, based on its record-setting Q3 report, but there are worrying signs out there that suggest it may not stay that way.
- 12/08/2022
|
Diodes Incorporated (DIOD) CEO Keh-Shew Lu on Q3 2022 Results - Earnings Call Transcript
- Diodes Incorporated (NASDAQ:DIOD ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Leanne Sievers - President of Shelton Group, Diodes IR Keh-Shew Lu - Diodes Chairman, President and CEO Brett Whitmire - CFO Emily Yang - SVP of Worldwide Sales and Marketing Gary Yu - SVP of Business Groups, Gurmeet Dhaliwal - Director of IR Conference Call Participants Matt Ramsay - Cowen Gary Mobley - Wells Fargo Securities David Williams - Benchmark Tristan Gerra - Baird William Stein - Truist Securities Operator Good afternoon, and welcome to Diodes Incorporated Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 11/07/2022
|
Diodes (DIOD) Tops Q3 Earnings and Revenue Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 7.53% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
What Makes Diodes (DIOD) a New Buy Stock
- Diodes (DIOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/28/2022
|
Diodes Incorporated to Announce Third Quarter 2022 Financial Results on November 7, 2022
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Monday, November 7, 2022 at 4:00 p.m.
- 10/17/2022
|
Diodes Inc.: The Growth Story Remains Intact
- Despite global macroeconomic headwinds, Diodes Inc. continues to generate ever-higher sales and earnings both on a quarter-on-quarter as well as a year-on-year basis. Management's nimble three-pronged strategy is well-suited to continue growing revenue and earnings despite weakening demands in some of the areas they sell to.
- 09/21/2022
|
3 Reasons Why Diodes (DIOD) Is a Great Growth Stock
- Diodes (DIOD) possesses solid growth attributes, which could help it handily outperform the market.
- 08/09/2022
|
Diodes Incorporated's (DIOD) CEO Keh-Shew Lu on Q2 2022 Results - Earnings Call Transcript
- Diodes Incorporated (NASDAQ:DIOD ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Leanne Sievers – Shelton Group, Investor Relations Keh-Shew Lu – Chairman, President and Chief Executive Officer Brett Whitmire – Chief Financial Officer Emily Yang – Senior Vice President of Worldwide Sales and Marketing Gary Yu – Senior Vice President of Business Groups Conference Call Participants Tristan Gerra – Baird William Stein – Truist David Williams – Benchmark Matt Ramsay – Cowen Operator Good afternoon, and welcome to Diodes Incorporated Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 08/05/2022
|
Diodes (DIOD) Q2 Earnings and Revenues Top Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 8.57% and 0.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Diodes Incorporated to Announce Second Quarter 2022 Financial Results on August 4, 2022
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Thursday, August 4, 2022 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its second quarter 2022 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gary Yu, Senior Vice President of Business Groups. The
- 07/14/2022
|
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
- Here are four top-performing liquid stocks, Qualys (QLYS), Southwest Airlines Co (LUV), Diodes Incorporated (DIOD) and Perion (PERI), which investors can add to their portfolio for solid returns.
- 06/24/2022
|
4 Top-Performing Liquid Stocks for Robust Returns in 2022
- Here are four top-performing liquid stocks, Cadence Design Systems (CDNS), Southwest Airlines Co (LUV), Diodes Incorporated (DIOD) and Nova (NVMI), which investors can add to their portfolio for solid returns.
- 06/10/2022
|
Is the Options Market Predicting a Spike in Diodes (DIOD) Stock?
- Investors need to pay close attention to Diodes (DIOD0 stock based on the movements in the options market lately.
- 05/31/2022
|
Diodes Inc: The Growth Story Is (Still) Intact
- DIOD is a company that averaged double-digit CAGR earnings-per-share growth over the past 20 years; it is still expected to grow EPS between 18.5% (FactSet) & 40.09% (S&P Market Intelligence). DIOD's products target end-markets with huge TAM and management have been making strategic moves to capitalize on the fastest-growing automotive market.
- 05/24/2022
|
Diodes Incorporated (DIOD) CEO Keh-Shew Lu on Q1 2022 Results - Earnings Call Transcript
- Diodes Incorporated (NASDAQ:DIOD ) Q1 2022 Results Conference Call May 4, 2022 5:00 PM ET Company Participants Leanne Sievers - Shelton Group, IR Gurmeet Dhaliwal - Director of Investor Relations Keh-Shew Lu - Chairman, President & CEO Brett Whitmire - CFO Emily Yang - SVP, Worldwide Sales and Marketing Gary Yu - SVP, Business Groups Conference Call Participants Matt Ramsay - Cowen Tristan Gerra - Baird William Stein - Truist Securities David William - Benchmark Operator Good afternoon, and welcome to Diodes Incorporated First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
- 05/04/2022
|
Diodes (DIOD) Q1 Earnings and Revenues Top Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 12.90% and 0.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2022
|
ON: Earnings Grow as Share Price Stagnates
- Earnings at ON Semiconductor Corporation ( ON , Financial) continue to rebound after falling off sharply in 2018 and 2019. In reporting earnings on Monday, May 2, the headline of its news release boasted of record revenue, margins and non-GAAP earnings per share for the first quarter of 2022.
- 05/03/2022
|
Diodes Incorporated to Announce First Quarter 2022 Financial Results on May 4, 2022
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Wednesday, May 4, 2022 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its first quarter 2022 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gary Yu, Senior Vice President of Business Groups. The Co
- 04/14/2022
|
onsemi Riding High, But The Ride Doesn't Have To End Soon
- onsemi Riding High, But The Ride Doesn't Have To End Soon
- 03/31/2022
|
Electric vehicle adoption is ‘a major uplift' for chipmakers, analyst says
- Truist Securities Managing Director William Stein joins Yahoo Finance Live's Julie Hyman and Brian Sozzi to discuss the significance of EV-focused chipmakers.
- 03/31/2022
|
Snap Up These 4 Top-Ranked Liquid Stocks for Robust Returns
- Here are four top-ranked liquid stocks, Diodes Incorporated (DIOD), Buckle (BKE), Ultra Clean Holdings (UCTT) and SeaWorld Entertainment (SEAS), which investors can add to their portfolio for returns.
- 03/23/2022
|
How Diodes (DIOD) Stock Stands Out in a Strong Industry
- Diodes (DIOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 03/15/2022
|
4 Top-Performing Liquid Stocks for Attractive Returns in 2022
- Here are four top-ranked liquid stocks, Diodes Incorporated (DIOD), Louisiana-Pacific (LPX), Skyline (SKY) and SeaWorld Entertainment (SEAS), which investors can tap for strong returns.
- 03/04/2022
|
Why Diodes (DIOD) Might be Well Poised for a Surge
- Diodes (DIOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 02/25/2022
|
4 Thriving Liquid Stocks to Boost Your Portfolio in 2022
- Here are four top-ranked liquid stocks, Cavco Industries (CVCO), Diodes Incorporated (DIOD), Houlihan Lokey (HLI) and Skyline (SKY), which investors can tap for strong returns.
- 02/18/2022
|
New Strong Buy Stocks for February 15th
- BCC, COLM, DIOD, PATK, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on February 15, 2022.
- 02/15/2022
|
Diodes (DIOD) Q4 Earnings and Revenues Surpass Estimates
- Diodes (DIOD) fourth-quarter 2021 results reflect solid top-line and EBITDA growth
- 02/10/2022
|
Diodes Incorporated (DIOD) CEO Keh-Shew Lu on Q4 2021 Results - Earnings Call Transcript
- Diodes Incorporated (DIOD) CEO Keh-Shew Lu on Q4 2021 Results - Earnings Call Transcript
- 02/09/2022
|
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 10.34% and 0.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2022
|
Diodes (DIOD) Earnings Expected to Grow: Should You Buy?
- Diodes (DIOD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/02/2022
|
Diodes (DIOD) Gains But Lags Market: What You Should Know
- In the latest trading session, Diodes (DIOD) closed at $85.87, marking a +1.78% move from the previous day.
- 01/28/2022
|
Diodes Incorporated to Announce Fourth Quarter and Fiscal 2021 Financial Results on February 9
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Wednesday, February 9, 2022 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its fourth quarter and fiscal 2021 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gurmeet Dhaliwal, Director of Investor R
- 01/19/2022
|
Diodes (DIOD) Gains As Market Dips: What You Should Know
- Diodes (DIOD) closed the most recent trading day at $109.81, moving +0.8% from the previous trading session.
- 12/31/2021
|
Is Diodes (DIOD) Stock Outpacing Its Computer and Technology Peers This Year?
- Here is how Diodes (DIOD) and Monolithic Power (MPWR) have performed compared to their sector so far this year.
- 12/31/2021
|
Diodes (DIOD) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Diodes (DIOD) closed at $110.25, marking a -0.07% move from the previous day.
- 12/29/2021
|
Diodes (DIOD) Outpaces Stock Market Gains: What You Should Know
- Diodes (DIOD) closed the most recent trading day at $106.49, moving +1.28% from the previous trading session.
- 12/22/2021
|
After A Dismal Performance Last Month, Diodes Incorporated Looks Set To Rally
- If you look at the change over the last five and ten days, too, the stock has returned -1% and -1% respectively, underperforming the broader market on both occasions.
- 12/13/2021
|
4 Top-Ranked Stocks From a Prospering Electronics Industry
- The Zacks Electronics - Semiconductors industry players, AMD, ASX, DIOD and CRUS, gain from the growing proliferation of 5G, AI, ML, IoT, Blockchain and consumer electronic devices.
- 12/03/2021
|
Is Diodes (DIOD) Stock a Solid Choice Right Now?
- Diodes (DIOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 12/03/2021
|
Earnings Estimates Rising for Diodes (DIOD): Will It Gain?
- Diodes (DIOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 11/23/2021
|
SAIC Grabs Space & Intelligence Contracts Worth $348M in Q3
- SAIC wins contracts worth $348 million in Q3 from the space and intelligence communities that involve highly-specialized services in digital engineering and information technology modernization.
- 11/22/2021
|
Best Momentum Stocks to Buy for November 17th
- AEL, CFBK, DIOD, and FLOW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 17, 2021.
- 11/17/2021
|
New Strong Buy Stocks for November 8th
- COST, DIOD, LEVL, MGPI, and PZZA have been added to the Zacks Rank #1 (Strong Buy) List on November 8th.
- 11/08/2021
|
Bull Of The Day: Diodes Inc (DIOD)
- This company has beaten the Zaks Consensus Estimate in each of the last four quarters and estimates are moving higher.
- 11/08/2021
|
Is Diodes (DIOD) Stock Outpacing Its Computer and Technology Peers This Year?
- Is (DIOD) Outperforming Other Computer and Technology Stocks This Year?
- 11/05/2021
|
Diodes (DIOD) Soars to 52-Week High, Time to Cash Out?
- Diodes (DIOD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 11/05/2021
|
Diodes' (DIOD) CEO Keh-Shew Lu on Q3 2021 Results - Earnings Call Transcript
- Diodes' (DIOD) CEO Keh-Shew Lu on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Diodes (DIOD) to Report Q3 Earnings: What's in the Cards?
- Diodes' (DIOD) third-quarter results are likely to benefit from robust adoption of its products in the automotive, industrial, communications and computing end-markets.
- 11/02/2021
|
Diodes Incorporated to Announce Third Quarter 2021 Financial Results on November 3
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Wednesday, November 3, 2021 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its third quarter 2021 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Gurmeet Dhaliwal, Director of Investor Relations &am
- 10/13/2021
|
High-Efficiency Class-D Stereo Audio Amplifier from Diodes Incorporated Saves Battery Power While Delivering Superior Sound Quality
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) introduces the PAM8965 Class-D stereo audio power amplifier with an integrated synchronous boost converter. This high-efficiency device is targeted for use in AI-enabled speaker systems and portable musical instruments - where elevated output power, extended battery life, and compact construction are all key requirements. Running off a 2.8V to 8.5V supply, the PAM8965 has the capability to drive 12W into 4Ω speakers via each of i
- 10/13/2021
|
Diodes (DIOD) Stock Sinks As Market Gains: What You Should Know
- Diodes (DIOD) closed at $94.88 in the latest trading session, marking a -0.36% move from the prior day.
- 09/24/2021
|
Is Diodes (DIOD) Stock Outpacing Its Computer and Technology Peers This Year?
- Is (DIOD) Outperforming Other Computer and Technology Stocks This Year?
- 09/24/2021
|
Diodes (DIOD) Stock Sinks As Market Gains: What You Should Know
- Diodes (DIOD) closed the most recent trading day at $94.83, moving -1.69% from the previous trading session.
- 09/15/2021
|
Bull Of The Day: Diodes Inc (DIOD)
- This stock consistently beats the Zacks Consensus Estimate and has a great valuation for a chip name.
- 09/13/2021
|
Is Diodes (DIOD) Stock Outpacing Its Computer and Technology Peers This Year?
- Is (DIOD) Outperforming Other Computer and Technology Stocks This Year?
- 09/08/2021
|
Precision-Adjustable Current Limit Power Switch from Diodes Incorporated Provides High Levels of Protection to Automotive Subsystems
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) introduces the AP22653Q programmable current limiting power switch. Streamlining power system design and assuring ongoing reliability, this automotive-compliant device provides a controlled and protected power path. It is rated to handle continuous load currents of up to 1.5A. Key applications include protection of vehicle USB ports and ECU supply rails, and infotainment and telematics subsystems. With a tight accuracy margin of
- 08/31/2021
|
8Gbps, 1/2 Lane PCIe 3.0/SATA3 Combo ReDrivers from Diodes Incorporated Support PC Industry's Modern Standby Mode
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has introduced the PI3EQX12902E/PI3EQX12904E to further strengthen its ReDriver™ product offering. These ReDrivers meet the Modern Standby mode requirements as outlined by Microsoft Corporation, and deliver elevated linearity and ultra-low jitter characteristics now expected in laptop, notebook, industrial PC, and embedded system designs. Operating from a 3.3V rail and in standby mode, the 1-lane PI3EQX12902E consumes 1.7mW with
- 08/25/2021
|
Is Diodes (DIOD) Outperforming Other Computer and Technology Stocks This Year?
- Is (DIOD) Outperforming Other Computer and Technology Stocks This Year?
- 08/23/2021
|
Earnings Estimates Rising for Diodes (DIOD): Will It Gain?
- Diodes (DIOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 08/20/2021
|
8 Semiconductor Stocks to Watch as Google Makes Its Own Chips
- Semiconductor stocks are a far broader set of companies than you might imagine. Here we discuss some of the best investments in the space now.
- 08/20/2021
|
22VPP/31VPP Selectable Output Piezo Sounder Driver from Diodes Incorporated Drives Higher SPL and Longer Runtimes
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) introduces the PAM8907 piezoelectric sounder driver, for maximizing sound pressure level (SPL) delivery from a ceramic/piezo sounder. The PAM8907 has a built-in synchronous boost converter, which extends SPL in battery-powered systems and outperforms other similar sounder drivers. The device is optimized for use in wireless trackers, industrial alarm systems, medical equipment, and domestic appliances. The wide 1.8V to 5.5V input
- 08/10/2021
|
Diodes Incorporated's (DIOD) CEO Keh-Shew Lu on Q2 2021 Results - Earnings Call Transcript
- Diodes Incorporated's (DIOD) CEO Keh-Shew Lu on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Is Diodes (DIOD) Stock Outpacing Its Computer and Technology Peers This Year?
- Is (DIOD) Outperforming Other Computer and Technology Stocks This Year?
- 08/06/2021
|
Diodes (DIOD) Surpasses Q2 Earnings and Revenue Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 7.14% and 1.30%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
Recap: Diodes Q2 Earnings
- Shares of Diodes (NASDAQ:DIOD) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 122.22% over the past year to $1.20, which beat the estimate of $1.12.
- 08/05/2021
|
Up 5% Last Week, Diodes Incorporated Stock Could Continue Its Rise
- Diodes Incorporated stock has seen an impressive rise of 5% over the past week and currently trades at $82 per share. This rally was driven by expectations of strong earnings growth in the company's upcoming Q2 2021 results, expected later this week.
- 08/03/2021
|
Tunable Linear ReDrivers from Diodes Incorporated Support Superior Levels of Signal Integrity on High-Speed DisplayPort 2.0 and HDMI 2.1 Interfaces
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) further reinforces its extensive linear ReDriver™ IC portfolio via the introduction of two new 3.3V-rated multi-lane active demux devices. These advanced ReDrivers address the demux needs now being set by the more graphically intense functions of mobile workstations, gaming PCs, and display dongles, while also still being fully optimized for the latest industrial computers and embedded systems hardware. Supporting 13.5Gbps data r
- 07/29/2021
|
8-Channel ReDriver with Internal Coupling Capacitors from Diodes Incorporated Enhances Signal Quality in High-Speed UPI 2.0 and PCIe 4.0 Interfaces
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has announced a new addition to its extensive range of linear ReDriver™ ICs. The PI3UPI1608 helps to significantly extend PCB trace lengths, while minimizing power consumption and associated bill-of-materials costs. Supporting speeds of up to 20Gbps, this UPI 2.0 and PCIe® 4.0 compliant device has eight differential channels. Its built-in coupling capacitors allow significant board area savings since use of external components ca
- 07/27/2021
|
4 Top Electronics Stocks From Prospering Electronics Industry
- The Zacks Electronics - Semiconductors industry players, AVGO, AMD, LSCC and DIOD, gain hugely from the growing proliferation of AI, ML and consumer electronic devices.
- 07/26/2021
|
Diodes (DIOD) Outpaces Stock Market Gains: What You Should Know
- In the latest trading session, Diodes (DIOD) closed at $77.20, marking a +1.78% move from the previous day.
- 07/23/2021
|
Diodes Incorporated to Announce Second Quarter 2021 Financial Results on August 5
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Thursday, August 5, 2021 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its second quarter 2021 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Laura Mehrl, Director of Investor Relations. The Compa
- 07/15/2021
|
3 Reasons Why Growth Investors Shouldn't Overlook Diodes (DIOD)
- Diodes (DIOD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 07/05/2021
|
Top Ranked Momentum Stocks to Buy for July 2nd
- Top Ranked Momentum Stocks to Buy for July 2nd
- 07/02/2021
|
Top Ranked Momentum Stocks to Buy for June 28th
- Top Ranked Momentum Stocks to Buy for June 28th
- 06/28/2021
|
Looking for a Growth Stock? 3 Reasons Why Diodes (DIOD) is a Solid Choice
- Diodes (DIOD) could produce exceptional returns because of its solid growth attributes.
- 06/18/2021
|
New Strong Buy Stocks for June 10th
- New Strong Buy Stocks for June 10th
- 06/10/2021
|
Automotive-Compliant LED Driver from Diodes Incorporated Simplifies Rear Lighting Designs
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has expanded its portfolio of devices supporting automotive exterior illumination with the introduction of the AL5873Q three-channel linear LED driver targeted at simplifying rear lamp cluster designs. Rated for 125°C ambient temperature operation, this automotive-compliant, AEC-Q100 Grade 1 qualified device meets the demands of next generation vehicle design – while also providing energy and space savings, hence, low overall sys
- 06/10/2021
|
Compact High Bandwidth 2:1 Mux/DeMux Switch from Diodes Incorporated Enables Routing with Superior Signal Integrity
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has added a new device to its range of passive multiplexer/demultiplexer (mux/demux) switches. Supporting data rates of up to 20Gbps, the PI2DBS16212A is a 4-to-2 differential channel switch IC, which offers bidirectional operation and is suited for use in high-performance IT equipment, including desktop PCs, laptops, workstations, and servers. Thanks to the proprietary design approach employed, Diodes Incorporated has optimized
- 06/08/2021
|
New Strong Buy Stocks for June 2nd
- New Strong Buy Stocks for June 2nd
- 06/02/2021
|
Is Diodes (DIOD) a Solid Growth Stock? 3 Reasons to Think " Yes "
- Diodes (DIOD) could produce exceptional returns because of its solid growth attributes.
- 06/02/2021
|
Industry-First, Automotive-Compliant Dual Power Rail I2C Bus GPIO Expanders from Diodes Incorporated Improve System Design and Flexibility
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has announced 16-bit PI4IOE5V6416Q and 34-bit PI4IOE5V6534Q bidirectional voltage-level translation general-purpose I/O (GPIO) expanders for automotive applications. Representing an industry first for the automotive industry, the automotive-compliant, AEC-Q100 Grade 2 qualified devices with dual voltage rail provide enhanced programmable I/O for next-generation low voltage microprocessors and microcontrollers via the I2C interfac
- 06/02/2021
|
New Strong Buy Stocks for May 28th
- New Strong Buy Stocks for May 28th
- 05/28/2021
|
New Strong Buy Stocks for May 24th
- New Strong Buy Stocks for May 24th
- 05/24/2021
|
3 Reasons Growth Investors Will Love Diodes (DIOD)
- Diodes (DIOD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 05/17/2021
|
New Strong Buy Stocks for May 17th
- New Strong Buy Stocks for May 17th
- 05/17/2021
|
1.8V 10Gbps USB Type-C & DisplayPort Linear ReDrivers from Diodes Incorporated Deliver Enhanced Signal Integrity Performance and Low-Power Operation
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has strengthened its position in the linear ReDriver™ IC market with the introduction of the 1.8V PI2DPX1066, PI2DPX1217, and PI2DPX1263. Suited for a range of applications including notebook and desktop PCs, smartphones, tablets, docking stations, gaming consoles, monitors, and virtual reality equipment, these parts use a lower level supply voltage and draw less power than competing products. They address the growing need within
- 05/11/2021
|
Diodes Incorporated (DIOD) CEO Dr. Keh-Shew Lu on Q1 2021 Results - Earnings Call Transcript
- Diodes Incorporated (DIOD) CEO Dr. Keh-Shew Lu on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Diodes (DIOD) Beats Q1 Earnings and Revenue Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 19.23% and 3.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
20Gbps Multi-Channel Mux/Demux from Diodes Incorporated Facilitates Better HD/UHD Video Signal Routing
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has further expanded its video passive multiplexer/demultiplexer (mux/demux) switch portfolio with the introduction of the 4-channel PI3WVR14412. Supporting up to 20Gbps operation, this 2:1/1:2 mux/demux device provides speeds beyond those of other products on the market - resulting in a 35% increase over what is offered by competitors. The PI3WVR14412 is fully compliant with both the DisplayPort™ 2.0 and HDMI2.1 interface standa
- 05/05/2021
|
Diodes Incorporated to Announce First Quarter 2021 Financial Results on May 6
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Thursday, May 6, 2021 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its first quarter 2021 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Laura Mehrl, Director of Investor Relations. The Company i
- 04/15/2021
|
High-Speed Bi-Directional Dual Supply Autosensing Level Shifter IC from Diodes Incorporated Aimed at Automotive Applications
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has expanded its family of voltage-level shifters, with the release of the PI4ULS3V304AQ. This advanced level shifting technology, featuring high degrees of flexibility, is proving vital to modern automobile design. It addresses the challenge of lower voltage microprocessors and microcontrollers incorporated into automotive systems, which are required to drive external devices operating at different voltage levels to their own (s
- 04/13/2021
|
8-Port PCIe 3.0 Packet Switch from Diodes Incorporated Provides Design Flexibility and Power Savings
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has introduced the PI7C9X3G808GP, a PCIe® 3.0 packet switch capable of delivering the elevated performance parameters mandated by modern data center, cloud computing, network-attached storage (NAS), and telecom infrastructure implementations. The packet switch supports 8-lane operation, accommodating 2-port, 3-port, 4-port, 5-port, and 8-port configurations. Cut-through, store and forward modes can be utilized with a packet forwa
- 03/31/2021
|
Weak FY '20 Performance Could Drag Diodes Incorporated Stock Lower
- Diodes Incorporated stock is up almost 50% since the beginning of 2020, and at the current price of around $82 per share, we believe that Diodes stock has around 15% potential downside. Why is that?
- 02/26/2021
|
Diodes (DIOD) is a Great Momentum Stock: Should You Buy?
- Does Diodes (DIOD) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 02/23/2021
|
Earnings Estimates Rising for Diodes (DIOD): Will It Gain?
- Diodes (DIOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 02/23/2021
|
Diodes Incorporated (DIOD) CEO Dr. Keh-Shew Lu on Q4 2020 Results - Earnings Call Transcript
- Diodes Incorporated (DIOD) CEO Dr. Keh-Shew Lu on Q4 2020 Results - Earnings Call Transcript
- 02/16/2021
|
Recap: Diodes Q4 Earnings
- Shares of Diodes (NASDAQ:DIOD) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 13.85% year over year to $0.74, which beat the estimate of $0.70.
- 02/16/2021
|
Diodes Incorporated Reports Fourth Quarter and Fiscal 2020 Financial Results
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights Completed the acquisition of Lite-On Semiconductor (LSC) on November 30, with initial purchase accounting and financing cost adjustments included in the fourth quarter 2020 GAAP results; Revenue was a record $350.4 million, which included $16.9 million of one month of revenue from LSC, and compares to $30
- 02/16/2021
|
Diodes (DIOD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Diodes (DIOD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/09/2021
|
Diodes Incorporated to Announce Fourth Quarter and Fiscal 2020 Financial Results on February 16
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Tuesday, February 16, 2021 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its fourth quarter and fiscal 2020 financial results. Joining Dr. Keh-Shew Lu, Chairman, President and Chief Executive Officer of Diodes Incorporated, will be Brett Whitmire, Chief Financial Officer; Emily Yang, Senior Vice President of Worldwide Sales and Marketing; and Laura Mehrl, Director of Investor Relatio
- 01/25/2021
|
Diodes Incorporated Stock To Return To Early 2020 Levels?
- Up a strong 137% since March, we believe Diodes Incorporated stock could see significant downside. Diodes, a semiconductor manufacturer catering to the consumer electronics, industrial, and automotive markets, saw its stock rise around 40% since the start of 2020.
- 01/15/2021
|
Semiconductor Stocks Are Worth Buying Today
- Semiconductors are integral to the future of all technology so any portfolio for the future is incomplete without semiconductor stocks.
- 01/07/2021
|
Automotive-Compliant, Two-Wire Hall Effect Switches With Self-Diagnostics From Diodes Incorporated Deliver High Sensitivity and Stable Performance
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) has announced a family of automotive-compliant, two-wire unipolar (AH323xQ/4xQ) and latch (AH327xQ/8xQ) switch integrated circuits (ICs) that provide high sensitivity and high stability over wide operating voltage and temperature ranges. The ICs are for use in automotive proximity- and position-sensing applications, including seatbelt buckle, power window, gear selector and seat position. The adoption of two-wire hall switches re
- 12/17/2020
|
Automotive-Compliant USB Type-C Port Protector from Diodes Incorporated Offers Overvoltage and Short Circuit Protection with Low Insertion Loss
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) today announced the automotive-compliant, AEC-Q100 qualified, and PPAP capable DPO2039DABQ 4-channel protection solution for USB Type-C® ports. DPO2039DABQ is targeted for use in applications including automotive head units, rear seat entertainment units, and in-car charging. There has been increasing adoption of the USB Type-C interface, particularly by automotive manufacturers keen to provide future-proof ports for smart device
- 12/10/2020
|
Diodes Incorporated Completes Acquisition of Lite-On Semiconductor Corporation
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) today announced the Company has completed its acquisition of Lite-On Semiconductor (TWSE: 5305) (“LSC”). The acquisition was initially announced August 8, 2019, with LSC shareholders approving the transaction on October 25, 2019. Following receipt of all necessary regulatory approvals and finalizing all other conditions, the transaction closed and became effective today with each LSC shareholder receiving TWD 42.50, or total cash
- 11/30/2020
|
Deep Dive: 11 semiconductor stocks expected to rise up to 47% over the next year
- Analysts expect semiconductor companies to increase sales at a faster pace than those of S&P 500 members in 2021 and 2022.
- 11/20/2020
|
15% Downside For Diodes Inc. Stock?
- Diodes Incorporated stock (NASDAQ: DIOD) is up 11% since the beginning of this year, and at the current price of around $63 per share, we believe that DIOD stock has around 15% potential downside.
- 11/13/2020
|
Diodes Incorporated (DIOD) CEO Keh-Shew Lu on Q3 2020 Results - Earnings Call Transcript
- Diodes Incorporated (DIOD) CEO Keh-Shew Lu on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Diodes: Q3 Earnings Insights
- Shares of Diodes (NASDAQ:DIOD) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 23.46% year over year to $0.62, which beat the estimate of $0.59.
- 11/09/2020
|
Single-Gate Logic Devices from Diodes Incorporated Target Automotive Applications Including Infotainment and ADAS
- PLANO, Texas--(BUSINESS WIRE)--Diodes Incorporated (Nasdaq: DIOD) today announced new additions to its expanding portfolio of automotive-compliant logic devices. The 74AHC1GxxQ (standard CMOS) and 74AHCT1GxxQ (TTL compatible) devices are AEC-Q100 grade 1 qualified, manufactured in IATF 16949 certified facilities, and are PPAP capable. Single-gate logic is used extensively in automotive systems, wherever a signal needs to be gated, buffered or inverted. The new devices offer 2-input single-gate
- 10/29/2020
|
Multi-Camera MIPI Switch from Diodes Incorporated Enables Smaller Product Profiles
- Diodes Incorporated (Nasdaq: DIOD) today announced the PI3WVR628 3-lane 2:1 switch measuring just 1.7mm x 2.4mm x 0.5mm. The MIPI®-compliant switch su
- 10/22/2020
|
COVID-19 Recovery Analysis: Discrete Diode Market | The Growing Adoption of Industry 4.0 Standards to Boost the Market Growth | Technavio
- The Global Discrete Diode Market will grow by $ 431.64 million during 2020-2024
- 10/21/2020
|
Industry’s First Automotive-Compliant 40V Dual MOSFET in 3.3mm x 3.3mm Package Introduced by Diodes Incorporated
- Diodes Incorporated (Nasdaq: DIOD) today announced the industry’s first automotive-compliant 40V dual MOSFET in a 3.3mm x 3.3mm package. The DMT47M2LD
- 10/15/2020
|
Diodes Incorporated (NASDAQ:DIOD) Shares Bought by PNC Financial Services Group Inc.
- PNC Financial Services Group Inc. raised its position in shares of Diodes Incorporated (NASDAQ:DIOD) by 121.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,055 shares of the semiconductor company’s stock after purchasing an additional 2,776 shares during the period. PNC Financial Services […]
- 10/04/2020
|
Stifel Financial Corp Invests $228,000 in Diodes Incorporated (NASDAQ:DIOD)
- Stifel Financial Corp acquired a new position in shares of Diodes Incorporated (NASDAQ:DIOD) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,502 shares of the semiconductor company’s stock, valued at approximately $228,000. Other institutional investors also recently made changes to […]
- 10/04/2020
|
Insider Selling: Diodes Incorporated (NASDAQ:DIOD) Director Sells $94,677.00 in Stock
- Diodes Incorporated (NASDAQ:DIOD) Director Michael R. Giordano sold 1,661 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $57.00, for a total value of $94,677.00. Following the completion of the sale, the director now owns 95,975 shares of the company’s stock, valued at […]
- 10/04/2020
|
Emily Yang Sells 4,354 Shares of Diodes Incorporated (NASDAQ:DIOD) Stock
- Diodes Incorporated (NASDAQ:DIOD) VP Emily Yang sold 4,354 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $54.74, for a total transaction of $238,337.96. Following the transaction, the vice president now owns 46,477 shares in the company, valued at $2,544,150.98. The transaction was […]
- 10/02/2020
|
High-Voltage Analog Multiplexers from Diodes Incorporated Provide Signal Distribution in Industrial IoT Applications
- Diodes Incorporated (Nasdaq: DIOD) today announced the introduction of the PS508 and PS509 analog multiplexers that are capable of switching signal vo
- 09/30/2020
|
Diodes Incorporated (NASDAQ:DIOD) Shares Sold by Fmr LLC
- Fmr LLC cut its holdings in shares of Diodes Incorporated (NASDAQ:DIOD) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 651,675 shares of the semiconductor company’s stock after selling 37,364 shares during the period. Fmr LLC owned 1.26% […]
- 09/17/2020
|
Diodes (DIOD) Investor Presentation - Slideshow
- The following slide deck was published by Diodes Incorporated in conjunction with this event.
- 09/01/2020
|
Diodes Inc. to Participate in the Jefferies Semiconductor, IT Hardware and Communications Infrastructure Conference on September 1
- Diodes Incorporated (Nasdaq: DIOD), today announced Brett Whitmire, Chief Financial Officer, Emily Yang, Vice President of Worldwide Sales and Marketi
- 08/25/2020
|
Stocks Tiptoe Ahead. News From the Fed Is Next.
- The minutes from the Fed’s policy-setting meeting at the end of July are due out at 2 p.m. Investors will look closely at the language for insights on how the bank sees the economy, and what it might do to support growth.
- 08/19/2020
|
US STOCKS-S&P 500, Nasdaq hit record highs as Apple crosses $2 trillion mark
- The S&P 500 and the Nasdaq indexes hit all-time highs on Wednesday as Apple became the first publicly listed U.S. company to cross $2 trillion in market capitalization, with strong results from retailers Target and Lowe's also lifting sentiment. Already crowned the most valuable listed company in the world, Apple Inc rose 1.4% to cross the milestone, while providing the biggest support to the three main indexes.
- 08/19/2020
|
US STOCKS-S&P 500, Nasdaq hit record highs as Apple tops $2 trillion in market value
- The S&P 500 and Nasdaq indexes hit all-time highs on Wednesday as Apple became the first publicly listed U.S. company to cross $2 trillion in market capitalization, with strong results from retailers Target and Lowe's also lifting sentiment. Already crowned the most valuable listed company in the world, Apple Inc rose 1.3% to cross the milestone, while providing the biggest support to the three main indexes.
- 08/19/2020
|
Potential Gilead Blockbusters Were Rejected By the FDA. Why That’s the ‘Near-Worst-Case Scenario’ for the Stock.
- The Food and Drug Administration rejected Gilead Sciences’ application for a would-be blockbuster arthritis drug Tuesday night, blindsiding investors.
- 08/19/2020
|
US STOCKS-S&P 500 notches record high for second day after Target, Lowe's results beat
- The S&P 500 and Nasdaq scaled record highs on Wednesday as results from retailers Target and Lowe's trounced estimates, a day after the S&P 500 completed its fastest recovery ever from a bear market. Big-box chain Target Corp jumped 9.5% after posting its best quarterly comparable sales growth and online revenue that nearly tripled.
- 08/19/2020
|
Dow Jones Today, Stocks Mixed; Target Heads Retail Rally; Biotechs Momenta, Gilead, Biomarin Swing Wild On Merger, FDA News
- Target and United Airlines staked early leads as financials led the Dow Jones today, but stocks struggled in mixed trade.
- 08/19/2020
|
US STOCKS-Wall St set to open higher after solid results from Lowe's, Target
- Futures pointed to slim opening gains for Wall Street's main indexes on Wednesday following results from retailers Target and Lowe's that trounced estimates, a day after the S&P 500 completed its fastest recovery from a bear market in history. Big-box chain Target Corp jumped 8.0% in premarket trade after posting its best quarterly comparable sales growth and online revenues that nearly tripled. Home improvement chain Lowe's Companies Inc rose 2.6% after beating estimates for quarterly same-store sales as it benefited from a surge in demand for its products from consumers stuck indoors.
- 08/19/2020
|
Target Stock Is Soaring, Gilead is Sinking and the Stock Market Is Trying for Another Record High
- Stocks moved slightly higher Wednesday morning following Tuesday’s record close in the S&P 500. Futures for the Dow Jones Industrial Average moved up 32 points—or 0.1%--matching the percentage point gain in the S&P 500. Futures for the Nasdaq Composite slipped 0.1%.
- 08/19/2020
|
Dow Jones Today, Futures Fight To Hold Gains; Target Heads Retail Rally; Gilead Swoons As FDA Balks
- Target and Southwest Airlines staked early leads, Intel led the Dow, but stock futures struggled to hold Wednesday's narrow early gains.
- 08/19/2020
|
Drug costs for COVID-19 patients plunge at U.S. hospitals, but may rise
- Medication costs for COVID-19 patients hospitalized in the United States have dropped sharply since May, reflecting advances in treatment, shorter stays and use of cheaper generic drugs. Research by the health data firm IllumiCare and exclusively shared with Reuters found that hospitals spent $1,090 per COVID-19 patient on medication in July. "We were throwing the kitchen sink at these patients and now hospitals are getting better at treating these infections," said G.T. LaBorde, chief executive of IllumiCare, a Birmingham, Alabama-based firm that works with hospitals and analyzes their electronic medical records.
- 08/19/2020
|
Stocks - Wall Street Opens Mixed as Target, Lowe's Surge; Dow up 30 Pts
- By Geoffrey Smith
- 08/19/2020
|
Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos says
- Gilead Sciences investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S. Food and Drug Administration in current form, its partner Galapagos said. The FDA wants further data and has expressed concerns about the overall benefit/risk profile of the 200 mg dose, said Galapagos. Galapagos is entitled to an approval milestone of $100 million for the approval of filgotinib in the U.S., and as a result Galapagos revised its 2020 operational cash burn guidance to between €490 and €520 million.
- 08/19/2020
|
Gilead Sinks After-Hours As FDA Rejects Rheumatoid Arthritis Application
- Gilead Sciences (GILD) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).Shares in Gilead fell 3.4% in Tuesday’s after-hours trading.The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.“We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program,” said Merdad Parsey, Chief Medical Officer of Gilead.The MANTA and MANTA-RAy studies are fully recruited, with topline results anticipated in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world and recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.The European committee recommended marketing authorization for filgotinib in the EU for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.The decision also affects Gilead partner Galapagos NV (GLPG), as the two companies are collaborating on the global development and commercialization of filgotinib in rheumatoid arthritis, and other inflammatory indications.Under the terms of the agreement with Gilead, Galapagos is entitled to an approval milestone of $100 million for the approval of filgotinib in the US, which was included in the Galapagos cash burn guidance. Following this CRL, Galapagos revises its full year 2020 operational cash burn guidance to between €490 and €520 million.Shares in Gilead are up 6% year-to-date and analysts have a cautiously optimistic Moderate Buy consensus on the stock’s outlook. That’s with ratings evenly split between hold and buy, and an average analyst price target of $83 (20% upside potential).Maxim’s Jason McCarthy reiterated his hold rating on the stock after the company reported disappointing 2Q earnings with product sales of $5.1B, down (10%) y/y and (7%) sequentially, missing consensus of $5.2B.Though the quarter was disappointing financially, McCarthy believes sales of GILD’s Covid-19 treatment remdesivir should help partially offset revenue decline stemming from COVID this year. (See Gilead stock analysis on TipRanks).Related News: Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment Krystal’s ‘Promising’ Cystic Fibrosis Drug Scores Orphan Designation Gilead ‘Very Pleased’ With Tango Collab, Boosts Cancer Targets To 15 More recent articles from Smarter Analyst: * Australia Inks Deal With AstraZeneca For Supply Of Covid-19 Vaccine Candidate * Verona Up 10% On Lung Trial Kick Off; Analyst Initiates Stock At ‘Buy’ * Etsy Declares $650M Convertible Note Offering; Stock Up 200% YTD * CytoDyn Seeking UK Fast-Track Approval For Leronlimab In Covid-19
- 08/19/2020
|
Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).
- 08/18/2020
|
Gilead announces another cancer deal
- Shares of Gilead Sciences Inc. gained 0.3% in premarket trading on Tuesday after the drugmaker on Monday evening announced a deal worth more than $6 billion with Tango Therapeutics. The collaboration, which began in 2018, has been expanded to allow Gilead option rights to 15 programs rather than the original five. Gilead will give Tango a $150 million upfront payment and make a $20 million investment. It can also option each of the programs for up to $410 million per program. While much of Gilead's news coverage this year has focused on the development of its COVID-19 treatment remdesivir, the company this year has also made a number of oncology deals, including a $4.7 billion acquisition of Forty Seven Inc., a partnership with Arcus Biosciences Inc. , a research deal with Teneobio Inc., and a $275 million stake in Pionyr Immunotherapeutics Inc. Gilead's stock is up 6.4% year-to-date, while the S&P 500 has rallied 4.7%.
- 08/18/2020
|
Gilead ‘Very Pleased’ With Tango Collab, Boosts Cancer Targets To 15
- Gilead Sciences (GILD) and Tango Therapeutics have announced an expanded collaboration focusing on targeted immune evasion therapies for cancer patients.Under the deal, which builds on a previous 2018 agreement, Tango will use its CRISPR-enabled functional genomics target discovery platform to identify novel immune evasion targets. The number of targets covered will expand from five to 15.Gilead will have options to worldwide rights for programs directed at these targets over the next seven years. Gilead will also have the right to pay option extension fees for Tango to lead activities through early clinical development, to which Gilead will retain its option rights. Tango will have the option to co-develop and co-promote the lead products for up to five programs in the US.“Since we signed the original agreement two years ago, we have been very pleased with the productivity of the collaboration and with the quality of scientific discovery that has come from this partnership,” said Gilead’s William A. Lee.“We are looking forward to working with Tango to run additional cancer context dependent screens to identify a broader set of targets based on our immuno-oncology strategy.”The collaboration excludes Tango’s lead programs, and Tango retains the rights to identify targets outside the immune evasion space.In respect of the deal, Gilead will make a $125 million upfront payment to Tango and a $20 million equity investment. It will also have the right to option up to 15 programs over the seven-years for up to $410 million per program in opt-in, extension and milestone payments. Tango will also be eligible to receive up to low double-digit tiered royalties on net sales.For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the US, and Tango will be eligible to receive milestone payments and royalties on ex-US sales.Shares in Gilead are up 6% year-to-date and analysts have a cautiously optimistic Moderate Buy consensus on the stock’s outlook. That’s with ratings evenly split between hold and buy, and an average analyst price target of $83 (20% upside potential).Maxim’s Jason McCarthy reiterated his hold rating on the stock after the company reported disappointing 2Q earnings with product sales of $5.1B, down (10%) y/y and (7%) sequentially, missing consensus of $5.2B.Though the quarter was disappointing financially, McCarthy believes sales of GILD’s Covid-19 treatment remdesivir should help partially offset revenue decline stemming from COVID this year.“However, what happens with remdesivir sales following the pandemic is unclear. It will be interesting to see if Gilead takes remdesivir to an inhaled formulation, which would change the equation; earlier COVID disease, more patients, take home therapy, etc” the analyst commented. (See Gilead stock analysis on TipRanks).Related News: Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment AstraZeneca Strikes First China Manufacturing Deal For Covid-19 Candidate Gilead Submits New Drug Application With FDA For Remdesivir More recent articles from Smarter Analyst: * Tiziana Spikes 25% In Pre-Market On Patent Win For Foralumab * ICE To Raise $6.5B In Bond Sale For Ellie Mae; Oppenheimer Cuts Stock To Hold * Wedbush Turns Bullish On Best Buy, Lifts PT * Truist Securities Lifts Alibaba’s PT Ahead Of 1Q Results This Week
- 08/18/2020
|
Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration
- Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics today announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer.
- 08/17/2020
|
Merck Is Barron’s Stock Pick This Week’s. Here’s Why.
- Shares of Merck (ticker: MRK), now around $83, are down 8% this year. For investors looking for a strong pharmaceutical play at a reasonable price, Merck should get attention. “Merck speaks softly and carries a big stick,” says David Risinger, a drug analyst at Morgan Stanley.
- 08/15/2020
|
Merck, Big Pharma’s Quiet Giant, Looks Like a Buy
- Shares of Merck (ticker: MRK), now around $83, are down 8% this year. For investors looking for a strong pharmaceutical play at a reasonable price, Merck should get attention. “Merck speaks softly and carries a big stick,” says David Risinger, a drug analyst at Morgan Stanley.
- 08/14/2020
|
A Field Guide to Covid-19 Vaccines and Antivirals
- Canadian small-cap biotech CytoDyn has asked the FDA to grant the company’s drug, Leronlimab, an emergency-use authorization to treat mild to moderate Covid-19 cases.
- 08/13/2020
|
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
- Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation. Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing https://reut.rs/3gTivT4.
- 08/13/2020
|
CalPERS more than doubles Gilead and Zoom Video stakes, trims Apple and Microsoft
- California Public Employees Retirement System (CalPERS) disclosed Wednesday that it more than doubled its shares stakes in Gilead Sciences Inc. and Zoom Video Communications Inc. , both of which have been beneficiaries of the COVID-19 pandemic, while it rebalanced its holdings of technology-behemoths Apple Inc. and Microsoft Corp. by trimming its stakes during the second quarter. As of June 30, the pension fund owned 10,528,157 million shares of Gilead, which makes COVID-19 vaccine candidate remdesivir, up from 4,353,093 shares as of March 31, while its Zoom Video stake increased to 341,358 shares from 61,070 shares. Among other companies with COVID-19 vaccine candidates, the stake in Moderna Inc. increased to 599,997 shares from 449,100 shares and the Inovio Pharmaceuticals Inc. holding nearly doubled to 322,441 shares from 176,365 shares. CalPERS trimmed its stakes in Apple to 9,171,757 shares from 10,190,498 shares and in Microsoft to 16,850,303 shares from 17,404,566 shares. Meanwhile, given the rallies in the stocks, the market value of CalPERS holding in Apple increased to $3.35 billion as of June 30 from $2.59 billion as of March 31, while the value of the Microsoft shares it held rose to $3.43 billion from $2.74 billion. The overall market value of CalPERS's equity holdings increased 22.7% to $101.41 billion, while the S&P 500 gained 20.0% in the second quarter.
- 08/12/2020
|
Is Diodes (NASDAQ:DIOD) Using Too Much Debt?
- David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- 08/12/2020
|
Is Now The Time To Look At Buying Diodes Incorporated (NASDAQ:DIOD)?
- Diodes Incorporated (NASDAQ:DIOD), is not the largest company out there, but it received a lot of attention from a...
- 08/12/2020
|
Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in August
- Vir Biotechnology Inc said on Tuesday it plans to start a mid-to-late stage trial of its COVID-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus. The company's therapy candidate, VIR-7831, is a monoclonal antibody that binds itself to the SARS-CoV-2 live virus and neutralizes it. Vir Biotech expects initial clinical data from the study to be available before the end of 2020.
- 08/11/2020
|
India's shortage of remdesivir is easing, says producer Cipla
- India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd. Remdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are authorised to make and sell generic versions in 127 developing nations. Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, Cipla's Global Chief Financial Officer, Kedar Upadhye, told Reuters.
- 08/11/2020
|
China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF). In China, Truvada for PrEP® is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. Truvada for PrEP should be taken once daily and used together with safer sex practices. Individuals must have a negative HIV-1 test immediately prior to initiating Truvada for PrEP.
- 08/11/2020
|
Gilead Submits New Drug Application With FDA For Remdesivir
- Gilead Sciences Inc. announced on Monday that it has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for remdesivir, its investigational antiviral for the treatment of patients with COVID-19.Gilead (GILD) said the filing is the “final tier” of the rolling NDA submission that was initiated on April 8. The antiviral, which will be sold under the brand name Veklury, is currently available in the US under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19.Remdesivir is a viral RNA polymerase inhibitor which means that it interferes with the production of viral genetic material, preventing the virus from multiplying.“Since the beginning of the pandemic, Gilead has worked with urgency to establish the efficacy and safety profile of Veklury, and we now have a robust data set supporting the evaluation of use of the drug across a range of hospitalized COVID-19 patient populations,” said Gilead’s Chief Medical Officer Merdad Parsey. “Today’s filing is an important milestone as we continue to partner with the US government and healthcare authorities around the globe to address the treatment needs of patients with COVID-19.”The application is supported by data from two randomized, open-label, multi-center Phase 3 clinical studies of remdesivir conducted by Gilead and the Phase 3 randomized, placebo-controlled study of remdesivir conducted by the National Institute of Allergy and Infectious Diseases (NIAID). These studies showed that treatment with remdesivir led to faster time to recovery compared with placebo and that a 5-day or 10-day treatment duration led to similar clinical improvement. Across both studies, remdesivir was generally well-tolerated in both the 5-day and 10-day treatment groups, with no new safety signals identified.Remdesivir has been approved by multiple regulatory authorities around the world, including the European Union and Japan. In countries where remdesivir has not been approved, including the US, it has the status of an investigational drug, which means that its safety and efficacy have not been established.Gilead has in recent weeks inked a number of manufacturing and supply agreements with drugmakers as the company has a target to produce more than 2 million remdesivir treatment courses by the end of this year, and several million more treatment courses in 2021.Shares in Gilead have advanced about 5% year-to-date. The $82.93 average price target implies another 22% upside potential in the shares in the coming 12 months.J. P. Morgan analyst Cory Kasimov reiterated a Hold rating on the stock with a $81 price target, saying that it is difficult to value GILD based on a P/E multiple given the potential lumpiness in future earnings.“Looking ahead, we believe much of the focus / debate will be around how big and durable of a product remdesivir can be as well as other opportunities for growth (whether it be HIV/PrEP, filgo, oncology/cell therapy, or through further M&A/BD),” Kasimov said. “Until these drivers emerge, we’re most comfortable at a Neutral rating.”The rest of the Street is cautiously optimistic on the stock with a Moderate Buy analyst consensus based on 10 Buy ratings versus 10 Hold ratings. (See Gilead stock analysis on TipRanks).Related News: Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment AstraZeneca Strikes First China Manufacturing Deal For Covid-19 Candidate Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease More recent articles from Smarter Analyst: * 3 “Strong Buy” Penny Stocks With Triple-Digit Upside Potential * MGM Spikes 14% As IAC Makes $1B Investment Amid Online Gambling Bet * Marriot Posts Wider-Than-Expected 2Q Loss, Sees 'Gradual Recovery' * Stephens Puts Trade Desk On Hold After 2Q Revenue
- 08/10/2020
|
Gilead files U.S. marketing application for remdesivir
|
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury® (remdesivir), an investigational antiviral for the treatment of patients with COVID-19. Veklury is currently available in the U.S. under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. The filing is the final tier of the rolling NDA submission that was initiated on April 8, 2020.
- 08/10/2020
|
Pfizer Inks Deal To Manufacture Gilead’s Covid-19 Remdesivir Treatment
- Pfizer Inc. announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir.Financial details weren’t disclosed. Under the terms of the agreement, Pfizer (PFE) will provide manufacturing services at its McPherson, Kansas facility to produce and supply remdesivir. With this deal, the drugmaker is joining a number of external manufacturing organizations as Gilead is under pressure to shore up supply of the investigational treatment for COVID-19.Gilead (GILD) expects to manufacture more than 2 million remdesivir treatment courses by the end of this year, and several million more treatment courses in 2021.Remdesivir is a viral RNA polymerase inhibitor which means that it interferes with the production of viral genetic material, preventing the virus from multiplying. Due to the current public health emergency, the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization for remdesivir for the treatment of hospitalized patients with severe COVID-19.“From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions,” Pfizer CEO Albert Bourla said. “Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic.”In a separate statement, the UK’s Hikma Pharmaceuticals announced that it signed a non-exclusive supply agreement with Gilead to produce remdesivir for injection at its factory in Portugal.Shares in Gilead have advanced about 7% year-to-date. The $82.93 average price target implies another 20% upside potential in the shares in the coming 12 months.Citigroup analyst Mohit Bansal earlier this month raised GILD’s price target to $80 from $78 and kept a Buy rating on the shares, as he expects Q3 remdesivir sales of $1.6 billion, supported mainly by US sales from 500,000 courses priced at $500 per vial using an 80%/20% commercial to government split.For Q4, Bansal estimates that remdesivir sales will be driven by 625,000 courses at $390 per vial to outside of the US countries. Both calculations would add up to $3.1 billion to second-half revenue.The rest of the Street is cautiously optimistic on the stock with a Moderate Buy analyst consensus based on 10 Buy ratings versus 10 Hold ratings. (See Gilead stock analysis on TipRanks).Related News: AstraZeneca Strikes First China Manufacturing Deal For Covid-19 Candidate Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease Moderna Secures $400M In Deposits For Supply Of Covid-19 Vaccine Candidate More recent articles from Smarter Analyst: * Northland Cuts Stamps.com To Hold Despite 2Q Earnings Beat * Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study * Foot Locker Pops 25% In Pre-Market On Surprise 2Q Sales, Profit Outlook * JMP Securities Lifts Zillow PT On Strong 2Q
- 08/10/2020
|
A Big Pension Bought GE, Merck, and Intel Stock. It Sold This Biotech.
- The State of Michigan Retirement System bought more General Electric, Merck, and Intel stock in the second quarter, and sold most of its investment in biotech stock Gilead Sciences.
- 08/09/2020
|
These Chip Stocks Jumped On Upbeat Earnings Reports
- Amid a mixed week for chip company earnings, two semiconductor stocks got a boost from beat-and-raise reports. SiTime and Synaptics cheered investors with their results and guidance.
- 08/07/2020
|
Pfizer Will Help Gilead Sciences Make Its Covid-19 Treatment, Remdesivir
- The drug giant is one of the firms that will manufacture remdesivir, Gilead Sciences’ experimental antiviral that got emergency approval in May as a treatment for Covid-19.
- 08/07/2020
|
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment
- The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said it will test its rheumatoid arthritis drug in combination with remdesivir.
- 08/07/2020
|
Pfizer to help manufacture Gilead's remdesivir
- Shares of Pfizer Inc. gained 1.0% in premarket trading on Friday after it announced that it will help manufacture Gilead Sciences Inc.'s COVID-19 treatment remdesivir as part of a multi-year agreement. Gilead's stock was up 0.6% on Friday before the market opened. This is a rare manufacturing deal between two of the world's largest drugmakers; "Together, we are more powerful than alone," Pfizer CEO Albert Bourla said in a news release. Remdesivir, which has received an emergency authorization from the Food and Drug Administration as a treatment for severely ill COVID-19 patients, has not been formally approved by the regulator. Since the start of the year, Pfizer's stock is down 2.3%, shares of Gilead have gained 5.9%, and the S&P 500 has rallied 3.6%.
- 08/07/2020
|
Pfizer signs deal to supply Gilead's remdesivir for COVID-19
|
UK's Hikma starts manufacturing COVID-19 treatment remdesivir for Gilead
- Hikma Pharmaceuticals has started manufacturing remdesivir, an approved treatment for COVID-19 from U.S.-based Gilead, for an undisclosed amount at its facility in Portugal, the British company's chief executive officer said. The company will supply the first batches of the antiviral drug "soon," and Gilead is expected to distribute the treatment, which was the first to be greenlit for the illness caused by the new coronavirus. "The terms of the deal are confidential, we are simply a contract manufacturer for Gilead - they order products from us as they expect the sales to be," CEO Siggi Olafsson told Reuters on Friday.
- 08/07/2020
|
Diodes (DIOD) Q2 Earnings and Revenues Top Estimates
- Diodes (DIOD) delivered earnings and revenue surprises of 8.00% and 2.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/06/2020
|
Diodes Incorporated Reports Second Quarter 2020 Financial Results
- Diodes Incorporated (Nasdaq: DIOD) today reported its financial results for the second quarter ended June 30, 2020.
- 08/06/2020
|
New coronavirus case records have been an 'abject failure' on part of the federal government: Doctor
- Emergency Medicine Physician at Columbia University Dr. Craig Spencer joins Yahoo Finance’s Kristin Myers to discuss the latest coronavirus outlook as U.S. cases surpass 3.5 million.
- 07/17/2020
|
Infectious disease specialists ask U.S. govt to ensure remdesivir supply
- U.S. infectious disease specialists this week asked the federal government to "use every authority it has" to ensure adequate supplies of the antiviral drug remdesivir as the number of people infected with the novel coronavirus continues to rise. In a letter to Vice President Mike Pence and Secretary of Health and Human Services (HHS) Alex Azar, the Infectious Diseases Society of America (IDSA) expressed concern that developed countries are relying on a single manufacturer for the only antiviral so far shown to be effective against COVID-19, the disease caused by the coronavirus.
- 07/17/2020
|
BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies
- The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy.Against this backdrp, BofA Securities issued an update to its view on COVID-19 market opportunities.Mixed Results From COVID-19 Market: The market remains dynamic but the results have been mixed, analyst Geoff Meacham said in a Friday note. Hydroxycholoroquine and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Kevzara faced setbacks, the analyst said. The FDA revoked the Emergency Use Authorization for hydroxycholorquine, and a Kevzara study in COVID-19 was stopped by Regeneron following a failed late-stage trial, he said. Yet there were meaningful wins, with vaccine and antibody development starting to accelerate, Meacham said."We recognize recent datasets have been early and necessarily incomplete -- with much still unknown about the virus -- resulting in outsized market movements for individual developers and the broader market." An antibody is unlikely to arrive before the fall, with any broadly available vaccine to follow by the second half of 2021 at best, the analyst said.With the ongoing progress, Meacham said he expects continued positive momentum through the summer.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: Applied DNA Surges On Encouraging Coronavirus Vaccine Data The Leading Trio: Pfizer Inc. (NYSE: PFE)/BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and AstraZeneca plc (NYSE: AZN)/University of Oxford are moving to the lead position, the analyst said.The Phase 1 updates from RNA vaccine producers Moderna and Pfizer/BioNTech are encouraging given that the vaccine candidates lead to the production of neutralizing antibodies at levels equal to or above convalescent serum, he said. There is still a long way to go, as real-world protection against symptomatic or severe disease is considered the true test for approval, Meacham said. BofA raised its estimates for AstraZeneca/University of Oxford candidate following reports of imminent positive data.Increased Remdesivir Penetration Likely: Following the hydroxychloroquine disappointment, BofA increased its estimates for the penetration of Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir.BofA lowered its price point and estimates for revenue in 2020 through 2022 to $825 million, $1.5 billion and $2.2 billion, respectively, with rapidly declining sales thereafter, factoring in the emergence of likely more effective antibodies, vaccines and herd immunity.Next-gen nextgen antivirals like inhaled remdesivir or Ridgeback's '2801 are unlikely before next year, according to BofA. Antibodies Could Score Over Antivirals: Antibodies are offering a more effective bridge to a widespread vaccine, given their effectiveness in treating other respiratory viruses, Meacham said. Eli Lilly And Co (NYSE: LLY) was the first to clinic with its AbCellera-partnered antibody, the analyst said. Regeneron's program, now in Phase 3, could garner more widespread use, he said.Along with Amgen, Inc. (NASDAQ: AMGN) and Lilly, the analyst estimates a collective peak market opportunity of about $11 billion, eclipsing the antivirals segment starting next year.Related Link: Moderna Analysts See Positives In Coronavirus Readout As Focus Shifts To Pivotal Phase 3 Study Latest Ratings for GILD DateFirmActionFromTo Jul 2020Morgan StanleyMaintainsEqual-Weight May 2020SunTrust Robinson HumphreyUpgradesSellHold May 2020SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for GILD View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO * Moderna Analysts See Positives In Coronavirus Readout As Focus Shifts To Pivotal Phase 3 Study * The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/17/2020
|
Coronavirus cases surge to new records in U.S.
- Yahoo Finance’s Anjalee Khemlani breaks down the latest on coronavirus with Alexis Christoforous and Brian Sozzi.
- 07/17/2020
|
I Built A List Of Growing Companies And Diodes (NASDAQ:DIOD) Made The Cut
- It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
- 07/17/2020
|
Hong Kong gives conditional greenlight to Gilead COVID-19 drug containing Remdesivir
- A Gilead Sciences medicine containing Remdesivir has received a conditional greenlight to be used to curb the coronavirus pandemic, Hong Kong officials said on Friday. The Hong Kong unit of the California-based drugmaker has to continue to submit additional data on the safety, effectiveness and quality of Veklury, which contains Remdesivir, the Drug Office of Department of Health said on its website. Remdesivir, which helped shorten hospital recovery times in a U.S. clinical trial, has been added to several countries' list of treatments against the disease that has killed over half a million people globally.
- 07/17/2020
|
Fauci urges U.S. to ‘regroup’ as COVID-19 cases surge
- Dr. Anthony Fauci says the U.S. needs to ‘regroup’ as coronavirus cases hit a new record. Harvard public health professor Dr. Howard Koh, a former top HHS official, speaks with Yahoo Finance’s Alexis Christoforous and Brian Sozzi about the latest on the spread of the virus.
- 07/17/2020
|
South Korea approves human trials of Celltrion's COVID-19 antibody drug
- South Korea on Friday approved an early stage clinical trial of Celltrion Inc's experimental COVID-19 treatment drug, making it the country's first such antibody drug to be tested on humans. Drugmakers worldwide are scrambling to develop vaccines and treatments for the flu-like illness caused by the novel coronavirus that has infected nearly 14 million people and killed more than 580,000 globally. Celltrion's antibody treatment is directed against the surface of the virus and designed to block it from locking on to human cells.
- 07/17/2020
|
5 Biopharma Stocks That Are Affordable And Growing
- Finding value among mature biopharma companies in the S&P; 500 is increasingly tricky. Here are five for investors to consider.
- 07/17/2020
|
Diodes Incorporated to Announce Second Quarter 2020 Financial Results on August 6
- Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Thursday, August 6, 2020 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its second quarter financial results.
- 07/16/2020
|
Individual Investors Stick With Stocks Amid Rising Anxiety
- Investopedia readers are more cautious than they were in May, with the majority fearing a market downturn in the next 3 months. Despite this, most are sticking with the stocks they’ve owned all year.
- 07/16/2020
|
Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2020 financial results will be released on Thursday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s second quarter 2020 financial results and will provide a business update.
- 07/16/2020
|
6 Health Care Stocks to Buy for the Second Half of 2020, According to Barron’s Investing Experts
- The conversations below are excerpted from our recent Midyear Roundtable, published on July 10. Telecoms and health-care companies have strong balance sheets, strong market positions, and undervalued shares. Glaxo, Gilead, and Roche are platform companies, as opposed to product companies.
- 07/15/2020
|
If You Own Gilead Sciences (GILD) Stock, Should You Sell It Now?
- On July 14, 2020, Silver Ring Value Partners LP released its Q2 2020 Investor Letter, a copy of which you can download here. The investment firm was founded in 2016 by Chief Investment Officer and Managing Partner Gary Mishuris. In its Q2 2020 Investor Letter, Silver Ring Value Partners LP reported 14 investments with a […]
- 07/15/2020
|
40V Synchronous Buck Converters from Diodes Incorporated Deliver High Efficiency with Low EMI for Automotive POL Applications
- Diodes Incorporated (NASDAQ: DIOD) today announced the AP64350Q/AP64351Q/AP64352Q series of automotive-compliant, 3.5A, synchronous buck converters for point of load (POL) applications. The AP6435xQ combines a low quiescent current with a wide input voltage range of 3.8V to 40V. The devices have been developed for use in automotive applications including infotainment systems, instrument clusters, telematics, advanced driver assistance systems (ADAS), and forward lighting.
- 07/14/2020
|
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today the closing of their option and co-development and co-commercialization partnership agreement signed on May 27, 2020.
- 07/13/2020
|
Sunbelt States Are Breaking the Wrong Record as Covid-19 Cases Surge
- States that have reopened too quickly may face an even worse fate in coming weeks unless steps are taken to contain the virus, one expert told Barron’s.
- 07/13/2020
|
U.S. Hospitals Need to Study How Well Remdesivir Really Works
- (Bloomberg Opinion) -- For months, hospitals have suffered the consequences of the country’s pandemic blunders. Intensive-care units have overflowed. Medical staff have struggled to get personal protective equipment, and have worked beyond exhaustion. It seems unfair to ask them to make up for another government misstep. But U.S. hospitals need to band together to run a clinical trial of the Covid-19 treatment remdesivir, even though the Trump administration has already decided the drug is what all hospitals should be using, going so far as to corner the worldwide market for it.Under the government’s deal with Gilead Sciences Inc., hospitals pay $3,200 per course of treatment for the antiviral drug — which is about 33% more than governments of other countries are to be charged. (The lower price will be available only to Veterans Affairs, the Indian Health Service and a handful of other U.S. government insurers, covering about 4% of the population.)The decision to commit so profoundly to remdesivir was based on evidence that was flimsy to begin with and is now outdated. One study showed that remdesivir improved Covid-19 recovery times and might reduce mortality in hospitalized patients. Another smaller study weakly supported the recovery-time benefit, but not the mortality one. (The data that Gilead released on Friday provided no additional insight into remdesivir’s potential benefits.) (Disclosure: I received a lecture fee from Gilead Sciences in 2017.)Both studies were published in May, a lifetime ago in pandemic years. In the spring, the coronavirus was targeting the elderly: In the first week of March, 60% of people admitted to the hospital with Covid-19 were 65 or older. The average age of subjects in the two studies was 59 and 65, respectively. In the first study, only 11% were under 40. By the last week of June, in contrast, 72% of patients admitted to hospitals with Covid-19 were under 65, and 42% were under 50. And antiviral treatments have varying risk-benefit ratios across ages. This is why the Centers for Disease Control recommends antiviral influenza treatment only for patients over 65 or under 2, absent other disease complications.There is every reason to suppose that the risk-benefit calculus for remdesivir will vary by age, too. Florida data show that hospitalized patients 65 and older have a 44% risk of death — nearly nine times that of people 25 to 44 (whose risk is 5%).What’s also changed since the remdesivir studies were done is the standard of care for Covid-19 patients. Doctors have learned that the common steroid dexamethasone reduces the risk of death for the severely ill by 20% to 35%. It’s not known whether remdesivir will work as well, or work at all in patients receiving dexamethasone.U.S. hospitals can answer that question and many others by following the example of the dexamethasone study. It was run across the U.K.’s National Health Service hospitals, with some patients randomly assigned to standard care, some to dexamethasone, and some to other promising therapies.Doctors throughout the U.K. were encouraged to enroll patients in the study, called RECOVERY, which involved simply collecting basic information such as their age and presenting complications. Random assignment to the various treatment arms ensured balance in all other factors that could affect the results.Ultimately, 15% of patients in Britain hospitalized with Covid-19 were enrolled. At the time the dexamethasone finding was published, the study already had 11,000 participants — 10 times as many as were included in the one study suggesting remdesivir is beneficial, and about five times as many as would be needed in a study to answer the question that the U.S. government already considers settled: Which patients do better — those receiving dexamethasone, or those receiving dexamethasone and remdesivir?The U.S. has no such collective approach to studying Covid-19 therapies. For American hospitals, accustomed to competing with one another, cooperating on a large scale would be a sea change. Only a few hospitals routinely coordinate clinical trials.But note that even the most conservative models project that tens of thousands of people will be hospitalized for Covid-19 this month, and most models put the number in the hundreds of thousands. With patient participation at even a fraction of what of the U.K. hospitals accomplished, a remdesivir study could be fully enrolled within days, and provide an answer within weeks.The hospitalization numbers are a reminder of a central tenet of clinical research: A study of very few can improve the well-being of very many. Because we are in a crisis, it’s tempting to skip this needed study and just assume remdesivir is more likely to help than hurt. But that could be wrong, and lead to more unanswered questions. What will we do when there is another treatment that might help people? And what about the one after that? Treatments can work synergistically, but they also can counteract one another. The only way to know how to use them is to study them separately and together.A study like this is also the most ethical way forward. The July supply of remdesivir is projected to be 92,000 treatment courses, far less than what hospitals will need. Many hospitals have run out already. So not all patients will be able to get the treatment, and randomization is a good way to decide who does. If shortages are to be chronic, that’s all the more reason to figure out which people benefit from remdesivir, and which do not.Since the early days of the pandemic, it’s been obvious that our hospitals need to keep up with scientific findings about new treatments. Now it’s apparent that they also need to run some of the studies themselves.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Peter B. Bach, a physician, directs the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center in New York. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/13/2020
|
South Korea: 1 in 3 Covid-19 Patients Improved With Gilead’s Remdesivir
- According to health authorities in South Korea, one third of seriously ill Covid-19 patients showed an improvement in their condition after being treated with Gilead’s (GILD) remdesivir drug, Reuters reports.However, additional research is still required to see if the improvement was connected to something other than the antiviral drug, for instance patients’ immunity or other therapies, the authorities said.The Korea Centers for Disease Control and Prevention (KCDC) deputy director Kwon Jun-wook was reporting results from an initial group of 27 patients in different hospitals.Out of the 27 patients given remdesivir, 9 saw their condition improved, 15 stayed in the same condition, and 3 patients deteriorated Kwon Jun-wook said. He added that the results had not been compared with a control group so further work was needed.Nonetheless, South Korea has already required a supply of 5,000 remdesivir treatments from Gilead in case of a second coronavirus outbreak. The company has already recorded almost 13,500 cases with 289 deaths.Meanwhile Australia’s Therapeutic Goods Administration (TGA) has just granted provisional approval to remdesivir (“Veklury”) as the first treatment option for Covid-19.“Remdesivir is the most promising treatment option so far to reduce hospitalisation time for those suffering from severe coronavirus infections” the Australian health administration stated, adding that remdesivir offers the potential to reduce the strain on Australia’s health care system. By reducing recovery times patients will be able to leave hospital earlier, freeing beds for those in need.Shares in Gilead rose 2% to $76.32 at the close of trading on July 10 taking the year-to-date advance to about 18%. The $80 average price target implies 5% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).“We believe that even in the likely case they are able to derive revenue from remdesivir, it would likely be only for the very near term, and the much more important potential value driver remains GILD’s ability to maintain their HIV leadership and revenue durability long-term” comments RBC Capital analyst Brian Abrahams. He has a buy rating on Gilead and $89 price target.Related News: Australia Provisionally Approves Gilead’s Covid-19 Treatment Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk Moderna Inks Deal With Rovi To Supply Potential Covid-19 Vaccine Outside US More recent articles from Smarter Analyst: * Amgen Pours A Further $421M Into China’s BeiGene * Qualcomm Buys Stake In Reliance’s Jio For $97.1M To Support 5G Rollout In India * Analog Devices Is Said To Be In Talks To Snap Up Maxim For About $20B * Tesla Sets Date For “Battery Day”, Analyst Says It Could Be 'Game-Changing'
- 07/13/2020
|
RPT-BUZZ-U.S. stocks weekly: Choppy
|
JGBs slip as stronger equities dent safe-haven demand
|
Nikkei marks 1-month closing high on virus drug hopes, autos gain
- Japan's Nikkei share average rose to a one-month closing high on Monday, tracking a rally on Wall Street as a positive analysis on a potential COVID-19 drug offset investor fears over surging virus cases. The benchmark Nikkei share average settled 2.22% higher at 22,784.74, its highest close since June 10, also helped by gains in auto stocks on upbeat industry data from China. U.S. stocks gained on Friday as Gilead Sciences Inc's antiviral remdesivir showed reduced risk of death in severely ill COVID-19 patients, but the company cautioned rigorous clinical trials were needed to confirm the benefit.
- 07/13/2020
|
Nikkei rises on virus drug hopes, auto stocks surge
|
A Giant Bank Bought Up Apple, AT&T and Gilead Stock. Here’s What It Sold.
- Norway’s biggest bank, DnB, increased investments in Apple, AT&T;, and Gilead stock in the second quarter. It also cut its position in networking firm Cisco Systems.
- 07/12/2020
|
Australia Provisionally Approves Gilead’s Covid-19 Treatment
- Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval to Gilead Sciences’ (GILD) remdesivir (“Veklury”) as the first treatment option for COVID-19.It has received provisional approval for use in adults and adolescent patients with severe COVID-19 symptoms who have been hospitalized. Remdesivir will not be available to Australians unless they are severely unwell, requiring oxygen or high-level support to breathe, and in hospital care.“Remdesivir is the most promising treatment option so far to reduce hospitalisation time for those suffering from severe coronavirus infections” the TGA states, adding that remdesivir offers the potential to reduce the strain on Australia’s health care system. By reducing recovery times patients will be able to leave hospital earlier, freeing beds for those in need.While this is a major milestone in Australia’s struggle against the pandemic, the administration emphasizes that the product has not been shown to prevent coronavirus infection or relieve milder cases of infection.Australia is the one of the first regulators to authorize the use of remdesivir for the treatment of COVID-19, following on from recent approvals in the European Union, Japan, and Singapore.Provisional approval, which is limited to a maximum of six years, was granted within 2 weeks of GILD’s submission of preliminary clinical data because there is the potential for substantial benefit to Australian patients, says the TGA.GILD can apply for full registration when additional clinical data to confirm the safety and efficacy of the medicine is available.Shares in Gilead rose 2% to $76.32 at the close of trading on July 10 taking the year-to-date advance to about 18%. The $80 average price target implies 5% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).“We believe that even in the likely case they are able to derive revenue from remdesivir, it would likely be only for the very near term, and the much more important potential value driver remains GILD’s ability to maintain their HIV leadership and revenue durability long-term” comments RBC Capital analyst Brian Abrahams. He has a buy rating on Gilead and $89 price target.Related News: Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk Moderna Inks Deal With Rovi To Supply Potential Covid-19 Vaccine Outside US More recent articles from Smarter Analyst: * Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk * Square Snaps Up Stitch Labs, As Analyst Finally Upgrades Stock * Alibaba’s CEO Sets Out Ambitious Goals; Sees 2B Customers By 2036 * Has Apple Surged Too Far, Too Fast? Analyst Weighs In
- 07/12/2020
|
Energy & Precious Metals - Weekly Review and Calendar Ahead
- Is the world underestimating the demand for oil amid the new explosion in coronavirus cases? Latest International Energy Agency stats suggest so, with the IEA forecasting more consumption that could help rebalancing. OPEC, meanwhile, is going the opposite way, calling for higher output from end-August that could lead to a tug-of-war in prices.
- 07/12/2020
|
Gilead Reveals Additional Data On Covid-19 Treatment Remdesivir
- Gilead Sciences (GILD) has announced encouraging additional data on remdesivir, the company’s investigational antiviral for the treatment of COVID-19.The data includes a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19.“In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality compared with standard of care – an important finding that requires confirmation in prospective clinical trials” the company stated.Separate subgroup analyses from the Phase 3 SIMPLE-Severe trial, including an evaluation of the safety and efficacy of remdesivir across different racial and ethnic patient subgroups in the US, found that traditionally marginalized racial or ethnic groups treated with remdesivir experienced similar clinical outcomes as the overall patient population in the study.Gilead also showed additional data on the company’s compassionate use program, which demonstrated that 83% of pediatric patients (n=77) and 92% of pregnant and postpartum women (n=86) with a broad spectrum of disease severity recovered by Day 28. No new safety signals were identified with remdesivir across these populations.To further the understanding of these results in individual patient cases, Gilead has initiated a global, open-label Phase 2/3 trial to evaluate the safety, tolerability and pharmacokinetics of remdesivir in pediatric patients from birth to less than 18 years of age. Gilead is also collaborating on a study for pregnant women.“We are working to broaden our understanding of the full utility of remdesivir. To address the urgency of the continuing pandemic, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir,” said Merdad Parsey, CMO of Gilead.“These data presented at the Virtual COVID-19 Conference shed additional light on the use of remdesivir in specific patient populations, including those that may be susceptible to higher rates of COVID-19 infection, as well as others that are particularly vulnerable, including children and pregnant and postpartum women” he added.Due to the current public health emergency, the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization for remdesivir for the treatment of hospitalized patients with severe COVID-19.Five-star analyst Jim Birchenough at Wells Fargo recently reiterated a Hold rating on Gilead saying that he remains skeptical on the longer-term commercial opportunity in view of emerging competition and potential vaccine progress. Indeed, the Street is cautiously optimistic on the stock with a Moderate Buy consensus based on 10 Buy ratings, 12 Holds and 3 Sells.Shares in Gilead rose 2% to $76.32 at the close of trading on July 10 taking the year-to-date advance to about 18%. The $80 average price target implies 5% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: Novavax Spikes 42% Pre-Market On $1.6B U.S. Funding For Covid-19 Candidate Gilead’s Covid-19 Remdesivir Therapy Gets Conditional European Nod Moderna Inks Deal With Rovi To Supply Potential Covid-19 Vaccine Outside US More recent articles from Smarter Analyst: * Square Snaps Up Stitch Labs, As Analyst Finally Upgrades Stock * Alibaba’s CEO Sets Out Ambitious Goals; Sees 2B Customers By 2036 * Has Apple Surged Too Far, Too Fast? Analyst Weighs In * Aurora Cannabis (ACB): Transformation on Track
- 07/12/2020
|
Morgan Stanley Sells 77,261 Shares of Diodes Incorporated (NASDAQ:DIOD)
- Morgan Stanley reduced its stake in shares of Diodes Incorporated (NASDAQ:DIOD) by 33.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 154,108 shares of the semiconductor company’s stock after selling 77,261 shares during the quarter. Morgan Stanley owned 0.30% of Diodes worth […]
- 07/12/2020
|
Australia's Victoria state records another day of high coronavirus infections
- Australia's second most-populous state on Saturday reported one of its highest daily increases in new coronavirus infections and warned the numbers would get worse before they got better as it began its first weekend under a six-week lockdown. Victoria state recorded 216 new cases of the virus that causes COVID-19 in the 24 hours to Saturday morning, down from a record 288 cases the previous day but still one of the biggest daily increases of any part of the country since the pandemic arrived. "It will get worse before it gets better," Victorian Premier Daniel Andrews told a televised news conference.
- 07/11/2020
|
HHS allocates Gilead's COVID-19 drug remdesivir to four hardest hit states
- The U.S. government has allocated more than 11,000 courses of Gilead Sciences Inc's COVID-19 treatment remdesivir to the four states now being hardest hit by the fast-spreading outbreak in the United States. The remdesivir is being distributed to Texas, Florida, California and Arizona on Friday and Monday, according to a U.S. Department of Health and Human Services (HHS) website https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/commercial-allocation-table.aspx. Remdesivir is in high demand as one of the only treatments so far shown to alter the course of COVID-19.
- 07/10/2020
|
Stock Market Today: Gilead Gives Stocks a Booster Shot
- Stocks rallied out of negative territory Friday after Gilead announced that remdesivir helped reduce COVID-19 mortality risk in a clinical trial.
- 07/10/2020
|
Market Recap: Friday, July 10
- Stocks rose Friday, with the Nasdaq Composite hit another record high. This comes after Gilead Sciences announced that its remdesivir treatment reduced the risk of death for COVID-19 patients, based on new data from the company. The Final Round panel breaks down the details.
- 07/10/2020
|
CANADA FX DEBT-Canadian dollar recovers from 10-day low after record jobs gain
- Canada's economy added 952,900 jobs in June, mostly in the service sector, as firms reopened following closures triggered by COVID-19, data from Statistics Canada showed. The price of oil, one of Canada's major exports, rose after the International Energy Agency (IEA) bumped up its 2020 demand forecast.
- 07/10/2020
|
Dow ends nearly 370 points higher as Nasdaq logs another record close
- Stocks ended higher in thin trade Friday, getting a lift from positive news on a coronavirus treatment. The Dow Jones Industrial Average rose around 369 points, or 1.4%, to end near 26,075, according to preliminary figures, while the S&P; 500 advanced around 33 points, or 1%, to end near 3,185. The tech heavy Nasdaq Composite rose nearly 70 points, or 0.7%, to end near 10,617, marking its third consecutive record close. Stocks shed premarket weakness after drug maker Gilead Sciences Inc. released potentially promising data about remdesivir that indicates the experimental COVID-19 drug may reduce deaths.
- 07/10/2020
|
CORRECTED-US STOCKS-Wall St climbs as Gilead data offsets virus fears; Nasdaq hits another record high close
- U.S. stocks rose on Friday and the Nasdaq posted its sixth record closing high in seven days as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 soothed investor worries over a record rise in coronavirus cases in the United States. Gilead's remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients, additional data from a late-stage study showed. Although the Nasdaq recorded another record closing high, it underperformed the Dow and S&P; 500, in a reversal of the recent trend.
- 07/10/2020
|
FOREX-U.S. dollar slides as vaccine news offsets surge in virus cases
- * Gilead news boosts risks sentiment * U.S. producer prices fall in June, dollar weaker * U.S. COVID cases post one-day record on Thursday * Yuan dips but stays near 4-month high * Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E (Recasts, adds new comment, updates prices) By Gertrude Chavez-Dreyfuss NEW YORK, July 10 (Reuters) - The dollar slipped on Friday, as its safe-haven allure diminished, on hopes of a potential vaccine for the novel coronavirus that outweighed concerns about the surge in infections in the United States and around the world. On Friday, Gilead Sciences Inc said additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.
- 07/10/2020
|
US STOCKS-Wall St gains as Gilead data offsets virus fears; Dow leads gains
- U.S. stocks rose on Friday as a positive update from Gilead Sciences Inc's antiviral drug to treat COVID-19 countered nerves over a record rise in coronavirus cases in the United States that threatens to further impact companies. In a reversal of the recent trend, the Dow and S&P; 500 were sharply outperforming the Nasdaq, which on Thursday registered its fifth record closing high in six days. Bank of America Corp, Citigroup Inc, JPMorgan Chase & Co and Goldman Sachs rose ahead of their financial results next week, which would mark the onset of the second-quarter earnings season.
- 07/10/2020
|
TREASURIES-Longer-term yields climb on optimism about COVID-19 recovery
- The yield on the benchmark 10-year U.S. Treasury note rose 2.8 basis points to 0.6332%, after dipping as low as 0.569% earlier in the session - its lowest level since April 22. Gilead Sciences reported that additional data from a late-stage study showed that its antiviral drug remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.
- 07/10/2020
|
Gilead says coronavirus drug remdesivir can reduce risk of death, but analysts need more proof
- Shares of Gilead Sciences Inc. gained 2.0% on Friday after the drugmaker shared potentially promising data about remdesivir that indicates the experimental COVID-19 drug may reduce deaths, though it noted the findings need to be confirmed.
- 07/10/2020
|
Health Stocks Are Among Goldman’s Top Election Volatility Plays
- (Bloomberg) -- U.S. equity investors are facing a turbulent four months as the presidential election heats up, and Goldman Sachs analysts scanned their coverage universe and found 38 stocks that investors can use to take advantage of that volatility with options.Large-cap health insurers and biotechs are at the top the list of stocks analysts led by Vishal Vivek see as swinging the most wildly, and they recommended buying at-the money-straddles. The strategy involves buying a put option and a call option with the same strike price and maturity date, which looks to profit from a jump in volatility.The recommendations come after the bank’s strategists earlier this week warned that mail-order ballots and Covid-19 disruptions could mean the final vote count gets delayed and roils stocks as investors wait to find out who will be president. In the latest polling Joe Biden has taken the lead with the support of 49.6% of voters, compared with Trump’s 40.9% backing, according to the RealClearPolitics average.S&P; 500 options show traders expect the index to move about 13% between now and the November election, that’s a narrower window than the health-care straddles Goldman is recommending. Biotechs including Amgen Inc., Biogen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., AbbVie Inc., Bausch Health Cos., Bristol-Myers Squibb Co., Johnson & Johnson, Eli Lilly & Co., Merck & Co. and Pfizer Inc. could oscillate in percentages from the mid-teens to over 30% between now and the election, according to Goldman’s analysis.Among health-care companies they list, Bausch Health has the widest expected move between now and January at 34%, the at-the-money straddle has a six-month implied volatility of 57%, which ranks in the 73rd percentile over the last year.While the battered reputation of drugmakers got a makeover as the sector races to come up with solutions to the Covid-19 epidemic, “how long this ‘goodwill’ lingers is an outstanding question, as we get closer to the November elections,” the analysts wrote in a note to clients.A Biden presidency could also alter the composition of health insurance, skewing it more toward government-tied insurance. That could drive 18% to 24% share moves for Anthem Inc., Cigna Corp., Humana Inc., and UnitedHealth Group Inc., the analysts predicted. Cigna has the second-highest expected move between now and January among health-care names at 24% and its six-month implied volatility of 39% ranks it in the 76th percentile.Energy is another key sector to watch. Biden’s plans around renewables could give stocks like First Solar Inc., Sunrun Inc., SunPower Corp. “a material boost,” while Concho Resources Inc., Devon Energy Corp., EOG Resources Inc. face the risk of tightened drilling regulations on Federal lands, Goldman said. The analysts also recommended hedging bets on legislative catalysts for Avangrid Inc., Pinnacle West Capital Corp., CVR Energy Inc., HollyFrontier Corp., PBF Energy Inc., Valero Energy Corp.They also identified stocks that may move on state ballots with “meaningful catalysts, but are likely under the radar of most generalist investors.” Propositions on employment rules will shake Lyft Inc. and Uber Technologies Inc. while DraftKings Inc. will hinge on votes over legal betting in states including Louisiana, Ohio and Massachusetts.DraftKings has rallied 71% year-to-date and the November at-the-money straddle shows options investors expecting shares to move 50% between now and expiration. The analysts noted the online gambling company’s 6-month implied volatility of 94%, ranks it in the 54th percentile on a one-year basis.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/10/2020
|
Dow jumps as Gilead says drug reduces COVID-19 death risk
- Dr. Alison Haddock,Emergency Medicine Physician and Assistant Professor of Emergency Medicine at Baylor University, joins Yahoo Finance’s Zack Guzman to break down the latest coronavirus developments.
- 07/10/2020
|
Stocks Rebound and Wipe Out Morning Losses. Gilead Lifts Hopes.
- Investors had been worried about rising coronavirus cases that are threatening to overwhelm hospitals, as well as a selloff in Asian equities, but those concerns were fading by the afternoon, helped by hopes we might be edging closer to a treatment for Covid-19.
- 07/10/2020
|
Europe Stocks Rise on Virus Drug Optimism, Positive Company News
- (Bloomberg) -- European stocks gained on Friday, boosted by upbeat corporate updates and optimism about a coronavirus treatment.The Stoxx Europe 600 Index closed 0.9% higher, with banks and autos leading gains, up more than 2% each. The benchmark extended its advance in afternoon trading after Gilead Sciences Inc. said its remdesivir virus treatment is associated with a 62% reduction in death risks compared with standard care, according to a new analysis of trial data.European shares have been trading in a tight range since mid-June, as investors weighed the unprecedented central bank and government stimulus against the effect of the pandemic on the economy. Caution ahead of the start of the second quarter earnings season, and rising virus infections in America have added to the worries.“Despite ongoing volatility, we continue to suggest investors stick to their long-term strategic equity allocations, but react to the larger swings by frequently rebalancing,” says Richard Flynn, U.K. managing director at Charles Schwab. “This allows portfolios to stay in gear by trimming into strength and adding into weakness, rather than trying to time short-term peaks and troughs.”Among notable movers, Danish brewer Carlsberg A/S jumped 6.4% after reporting preliminary earnings, while satellite communications provider SES SA surged after an upgrade from Goldman Sachs Group Inc.Sentiment in the region was also helped after the European Union made a new effort to achieve its economic stimulus plan by offering sweeteners to critics of the package.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/10/2020
|
US companies seeking capital during pandemic test bank market's new normal
- Bank lenders for high-quality US companies are taking different refinancing avenues as they seek to extend maturities on billions of US dollars in loans at a time when the Covid-19 pandemic has made liquidity a top priority. Corporations that historically kept their credit agreements intact while extending maturities are now making significant changes to the loan documents accepting risk-mitigating concessions on pricing, terms and the loans’ longevity, while others seem exempt from the new requirements. Gilead Sciences, IBM and Ford Motor Co have tapped the market recently, with transactions that have pushed maturities out and ensured their access to capital following company-specific strategies that reflect different lenders’ perceptions of the credits and the changing times.
- 07/10/2020
|
FOREX-Yen rises on renewed surge in virus cases; dollar index falls
- * U.S. producer prices fall in June, dollar weaker * U.S. COVID cases post one-day record on Thursday * Yuan dips but stays near 4-month high * Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E (Adds new comment, FX table, updates prices, changes byline, dateline; previous LONDON) By Gertrude Chavez-Dreyfuss NEW YORK, July 10 (Reuters) - The safe-haven Japanese yen climbed to a two-week peak against the dollar on Friday, lifted by concerns about a surge in coronavirus infections in the United States and around the world. The yen was on track to post its largest daily percentage gain against the dollar in about a month. The greenback fell against a basket of major currencies, pressured by weaker-than-expected U.S. producer prices in June as well as positive news about the potential coronavirus vaccine remdesivir that hurt the dollar's status as a safe haven.
- 07/10/2020
|
Gilead Says New Analysis Suggests Remdesivir Reduces Covid-19 Deaths
- Gilead cautioned that the finding —a 62% reduction in Covid-19 deaths—needed to be confirmed in clinical trials. An earlier study of remdesivir found that the drug shortened the duration of a Covid-19 infection, but mortality benefit did not hit statistical significance.
- 07/10/2020
|
Oil Gets Rare, Late Week Boost From IEA Demand Outlook
- The global energy agency that rarely helps the positive case in oil has given a friendly boost to those long crude, just as the week comes to an end. Crude prices jumped more than 1% on Friday after the International Energy Agency bumped up its 2020 forecast for global oil demand, lifting a market that took its worst hammering in six weeks in the previous session. The IEA’s outlook on oil has typically been dour over the past few years, putting it at odds with the Saudi-dominated OPEC — or Organization of the Petroleum Exporting Countries — whose members are determined to keep crude prices supported under any condition.
- 07/10/2020
|
Oil Rebounds on Dollar Weakness Yet Demand Woes Linger
- (Bloomberg) -- Crude reversed losses amid a weaker U.S. currency, easing a decline this week that’s been led by a gloomy demand outlook with virus cases surging. Oil rose 0.9% in New York on Friday. The dollar weakened after Gilead Sciences Inc. said its Remdesivir treatment cut Covid-19 mortality risk by 62%, bolstering the appeal of commodities traded in the U.S. currency. Still, crude is on track for a 2.5% weekly decline. The coronavirus pandemic is far from easing around the world and the International Energy Agency said a jump in cases could derail the market recovery. “Between record storage levels and the fear of further demand destruction as a result of Covid, crude oil has been under pressure all week,” said Bob Yawger, director of the futures division at Mizuho Securities USA.The rally in crude driven by the easing of lockdowns has stalled near $40 a barrel as traders weighed the resulting acceleration of infections. California, Texas and Florida have recorded some of their biggest daily gains in cases and deaths this week. There’s a growing risk that the renewed outbreaks will impede efforts to reopen the economy.“America is still in the throes of the pandemic and this spells bad news for the oil demand outlook,” said Stephen Brenock, an analyst at brokerage PVM Oil Associates. “Against this backdrop, upside potential for oil prices will remain in short supply.”While the The IEA said demand should rebound sharply over the next three months as economic activity resumes, the agency also warned a flare-up of the virus, which is raging across several U.S. states and re-emerging in Asia, is “casting a shadow over the outlook.”See also: Revival of Libya’s War-Torn Oil Industry to Be Slow and CostlySupply could also become more abundant as Libya’s National Oil Corp. announced it would lift force majeure on all exports following months of near-zero shipments. The Kriti Bastion tanker has started loading 730,000 barrels of crude at Es Sider, with the cargo heading to Italy, according to port operator Waha Oil Co.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/10/2020
|
Gildead: Remdesivir reduces deaths in COVID-19 patients
- Yahoo Finance’s Alexis Christoforous and Brian Sozzi discuss the latest coronavirus news with Yahoo Medical Contributor and Columbia University Associate Professor of Emergency Medicine, Dr. Dara Kass.
- 07/10/2020
|
How Did Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Fare Against The Industry?
- One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- 07/10/2020
|
Dow and broader stock-market futures turn positive amid upbeat report on Gilead's experimental coronavirus treatment
- U.S. stock-index futures turned positive on Friday after a report from Gilead Sciences indicated that its experimental treatment for coronavirus was seeing positive results in reducing deaths. Futures for the Dow Jones Industrial Average were up 0.1% at 25,600, those for the S&P; 500 index were trading up 0.1% at 3,144, while Nasdaq-100 futures advanced 0.1% at 10,740. Gilead published a report on Friday saying that its antiviral drug remdesivir showed that it reduced the risk of death for coronavirus patients by 62% compared with standard care alone. The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said.
- 07/10/2020
|
A new Gilead analysis indicates remdesivir can reduce death but company says finding 'requires confirmation'
- Shares of Gilead Sciences Inc. gained 2.0% in premarket trading on Friday after the drugmaker disclosed findings from a new analysis of previously disclosed clinical trial data that found the experimental therapy remdesivir can reduce the risk of mortality in COVID-19 patients by 62%, when compared to the standard of care. Gilead said the mortality data point is "an important finding that requires confirmation in prospective clinical trials." The new analysis is not from a randomized, placebo-controlled clinical trial; it stems from a comparative, pre-planned analysis of 312 severely ill participants in a randomized, open-label Phase 3 trial and a real-world retrospective cohort of 818 patients with COVID-19 who had similar clinical attributes to those included in the trial and received remdesivir as part of their treatment. The new analysis may also help reinforce previous conclusions from a randomized, placebo-controlled National Institutes of Health trial that found remdesivir can reduce recovery times, a finding that was published in April and contributed to the Food and Drug Administration's decision in May to grant an emergency use authorization to remdesivir. Gilead's stock has gained 14.9% year-to-date, while the S&P; 500 is down 2.4%.
- 07/10/2020
|
Gilead says additional data on remdesivir shows improved clinical recovery
|
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
- Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment outcomes with remdesivir. The data are being presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual) and include a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19. In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality compared with standard of care – an important finding that requires confirmation in prospective clinical trials.
- 07/10/2020
|
Australia approves Gilead's remdesivir for COVID-19 treatment
- Australia has granted provisional approval to Gilead Sciences Inc's remdesivir as the first treatment option for COVID-19 in the country, the Therapeutic Goods Administration (TGA) said on Friday. The approval is for adults and adolescent patients with severe COVID-19 symptoms and have been hospitalised, the Australian regulator said. Remdesivir has become the treatment of choice for many countries against severely ill COVID-19 patients after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial.
- 07/10/2020
|
Gilead to deliver more remdesivir to Germany, Europe from the Fall - WiWo
- Gilead Sciences Inc plans to make more of its drug remdesivir available for Germany and Europe from the Fall and will decide how much each country gets based on the rate of infection, the drugmaker's Germany boss told a German magazine. Bettina Bauer, German managing director of Gilead, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to two million treatment cycles in December. Remdesivir is currently the only drug granted a conditional marketing authorisation by the EU for its use in COVID-19 patients.
- 07/09/2020
|
Coronavirus latest: Wednesday, July 8
- Cases of coronavirus continue to rise in the United States, with states breaking daily records and no clear insight into how to curve the outbreak. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
- 07/08/2020
|
CORRECTED-Gilead begins testing inhalable form of remdesivir for COVID-19
|
Gilead's stock drops as it starts early-stage trial for inhaled remdesivir
- Shares of Gilead Sciences Inc. fell 1.4% in trading on Wednesday after the drugmaker said it started a Phase 1a clinical study testing an inhaled version of its experimental COVID-19 drug remdesivir. The Food and Drug Administration in May granted an emergency use authorization to an intravenous form of remdesivir as a treatment for some severely ill COVID-19 patients. Gilead first announced plans in June for the new randomized, placebo-controlled clinical trial, which has enrolled 60 healthy adults. "Delivering remdesivir directly to the primary site of infection with a nebulized, inhaled solution may enable more targeted and accessible administration in non-hospitalized patients and potentially lower systemic exposure to the drug," Dr. Merdad Parsey, Gilead's chief medical officer, said in a statement. Gilead's stock has gained 15.8% year-to-date, while the S&P; 500 is down 2.6%.
- 07/08/2020
|
India's Cipla set to undercut rivals with generic remdesivir -sources
- Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.
- 07/08/2020
|
South Korea seeks remdesivir to treat over 5,000 COVID patients -lawmaker
- South Korea has asked Gilead Sciences Inc's to supply enough of its anti-viral drug remdesivir to treat more than 5,000 COVID-19 patients in preparation for a potential second wave of infections, an opposition lawmaker said on Wednesday. One of the few treatments shown to alter the course of COVID-10, remdesivir is in high demand, but there are concerns about its availability after Gilead allocated nearly all of its supply to the United States over the next three months. In a letter sent to Gilead on June 3, South Korea had requested doses for 360 patients who are in urgent need of the drug, and for enough to have ready for an additional 5,000 patients in the event of a second wave of infections.
- 07/08/2020
|
Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders
- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP utilization on HIV prevention strategies and associated risk behaviors. Findings presented included results from an online survey conducted by The American Academy of HIV Medicine (AAHIVM) to understand potential changes in behavior among pre-exposure prophylaxis (PrEP) users and prescribers in the United States during the height of COVID-19 SIPOs. There were 598 total respondents – 409 PrEP users and 189 PrEP prescribers. While most prescribers (90 percent) reported recommending no change in PrEP regimen, about one-third (33 percent) of PrEP users discontinued therapy voluntarily, mostly (85 percent) due to low perceived HIV risk associated with decreased sexual activity. Only 8 percent of those users who discontinued PrEP cited inability to access PrEP medications. Nearly all prescribers (95 percent) were able to successfully prescribe PrEP despite limitations caused by SIPOs.
- 07/08/2020
|
State of Tennessee Treasury Department Buys 3,322 Shares of Diodes Incorporated (NASDAQ:DIOD)
- State of Tennessee Treasury Department lifted its stake in shares of Diodes Incorporated (NASDAQ:DIOD) by 19.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,109 shares of the semiconductor company’s stock after purchasing an additional 3,322 shares during the quarter. State of Tennessee […]
- 07/05/2020
|
Invesco Ltd. Reduces Position in Diodes Incorporated (NASDAQ:DIOD)
- Invesco Ltd. lowered its position in shares of Diodes Incorporated (NASDAQ:DIOD) by 37.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,335 shares of the semiconductor company’s stock after selling 139,570 shares during the period. Invesco Ltd. owned […]
- 07/04/2020
|
After Gilead Reveals Remdesivir Pricing, Analyst Sees Significant Revenue Upside
- The coronavirus marches on, but healthcare names all over the world are fighting back. Earlier this week, Gilead Sciences (GILD), the manufacturer of COVID-19 antiviral drug remdesivir, revealed the pricing plan for the treatment. A five-day course of remdesivir will be sold to governments of developed nations, including the US, for a price of $2,340 ($390 per vial). US private health insurers will need to fork up $3,120 for the course ($520 per vial). Other countries, though, will find it difficult to get hold of the treatment over the next three months. The Trump administration has purchased over 500,000 doses, which amounts to July’s total production, and 90% of Gilead’s expected output in August and September. Overall, in 2020, Gilead expects to produce up to 3 million courses. Next year, Gilead has set its sights on manufacturing between 600,000 and 800,000 courses a month. The news was greeted with enthusiasm by investment firm Leerink Partners. Firm analyst Geoff Porges increased the revenue forecast for Gilead “by $800 million to $1.8 billion in each of the next three years.” The 4-star analyst expects remdesivir to bring in $1.5 billion of revenue in 2020, rising to $8.5 billion in 2021, and $8.6 billion by 2023. Hopefully, remdesivir’s impact will match that of the 2014 launch of its first HCV medicine, Sovaldi, when GILD’s share price increased by 54% in the three quarters following the launch. Porges said, “We regard the price and its announcement positively, as it establishes a responsible but still profitable benchmark for COVID treatment pricing generally and for Gilead specifically. The strengthened RDV supply together with higher RDV pricing for ex-US markets and stockpiling has significantly increased our forecasts for RDV.” However, Porges tempered expectations by adding, “This forecast still has massive uncertainty given the varying trajectory of the pandemic around the world, the outlook for vaccines, the prospects for alternative and additional medicines, and the appetite of government agencies for stockpiling.” As a result, Porges reiterated an Outperform rating and boosted the price target to $95 (up from $94). Gains of 25% could be heading investors’ way should Porges’ forecast materialize over the coming months. (To watch Porges’ track record, click here) The rest of the Street takes a cautiously optimistic approach to Gilead. A Moderate Buy consensus rating is based on 11 Buys, 12 Holds and 4 Sells. There’s upside of 6%, should the $80.22 average price target be met in the year ahead. (See Gilead stock analysis on TipRanks)
- 07/02/2020
|
Indonesia seeking its own COVID-19 vaccine amid worry about access
- Indonesia is working to produce its own COVID-19 vaccine next year, amid growing anxiety that developing countries could have difficulty getting access to a future jab, the head of Indonesia’s national COVID-19 research team said Thursday. “The production capability and capacity of biotech companies in the world is, we know, limited, and global supply chains also have challenges,” Ali Ghufron Mukti, head of the innovation team at Indonesia’s research and technology ministry, told a streamed press conference alongside the country’s foreign minister.
- 07/02/2020
|
$600 or $3,120? Gilead Puts a Price Tag on Covid-19 Relief
- (Bloomberg Opinion) -- While a world awash in a pandemic awaits a coronavirus vaccine, Gilead Sciences Inc. is bringing a treatment to market.Remdesivir is an experimental drug that may help Covid-19 patients recover more quickly — but it doesn’t immunize them. Its price tag is $600 for a series of six treatments for patients who live in developing countries where Gilead, to its credit, allows a generic version to be sold. If patients live in a developed country and the government insures them or provides their health care, it costs $2,340. If they have private insurance and live in the U.S., it costs $3,120. (And that’s if six treatments work; some patients are expected to need 12 treatments, so those prices could double.)That sounds like a lot of money to me. But it doesn’t sound like a lot to Gilead’s chief executive officer, Daniel O’Day.O’Day noted in a letter posted on his company’s website on Monday that remdesivir is priced “well below” the “value” it provides. He defined that “value” as the amount Gilead has determined providers and patients save (about $12,000) by shortening treatment times in hospitals. “There is no playbook for how to price a new medicine in a pandemic,” O’Day wrote. “In normal circumstances, we would price a medicine according to the value it provides.”Using already exorbitant hospitalization costs as a benchmark for value is a neat trick, but Geoffrey Porges, a prominent biotechnology and pharmaceuticals analyst, is on the same page as O’Day.“It’s unprecedented to price the drug below the medical costs that it’s saving,” Porges told NPR, saying he thought remdesivir could save as much as a whopping $40,000 per patient. Wait, there’s more. “That ignores the enormous societal value that everybody else gets from making a patient less infectious, for getting a patient back into the community, for getting them back to work sooner,” he added. “All of those societal benefits aren’t even considered in this price.”Just for speculation’s sake, what would all those societal benefits add up to? Another $40,000 per patient? $100,000? $1 million? Pick your number because any figure, in the context of squishy and hard-to-quantify externalities, will be squishy and hard to quantify.Porges has also invoked history when weighing in on remdesivir’s price tag. “If you are going to war, or preparing for war in a capitalist country, you have to let business make money out of the process or business won’t work,” he wrote in a note to investors in early June, quoting a famous diary entry of former Secretary of War Henry Stimson during World War II.There’s no question that the world is at war with Covid-19, and there’s nothing wrong with a business making money, of course. Profits are a fundamental incentive. But they frequently aren’t the only incentive. And the interesting and troubling arguments raised by remdesivir’s price have plagued the pharmaceutical and biotechnology businesses for quite some time. Mother Nature, clothed in a pandemic, is forcing an overdue adjudication of their merits.Big Pharma has asserted for years that hefty prices are rewards for hefty expenses, traditionally identified as all of the research and development spending that contributes to the cost of inventing and developing blockbuster drugs. Pharma’s R&D; costs are relatively lofty compared to other industries and may amount to about 17% of revenue — a figure surpassed only, perhaps, by the R&D; spending of semiconductor manufacturers and some other tech companies. A Tufts University study published in 2016 said it costs, on average, about $2.6 billion to develop a drug that wins the federal government’s marketing blessing. The Tufts research group that prepared the study receives a significant portion of its funding from the industry, and its estimate was based on an analysis of 106 randomly selected drugs that 10 pharmaceutical companies tested on human subjects between 1995 and 2007.Public Citizen, a consumer advocacy group, has fileted the Tufts study, saying only $1.4 billion of the $2.6 billion figure represents actual developments costs (with the other $1.2 billion accounted for as opportunity costs incurred by not pursuing other investments). Public Citizen said that even the $1.4 billion figure contained inflated assumptions about expenditures, derived in part from a focus on only the most expensive drugs. It said the Tufts study didn’t fully account for generous government grants that typically provide, perhaps, as much as a fifth of pharma companies’ research spending. Pharmaceutical companies also often enjoy monopoly pricing and have used patent laws to keep competitors at bay.Sometimes, Big Pharma just buys pre-developed drugs, which means its R&D; costs are even less substantial. For example, more than a decade ago, an Emory University professor who was also a government researcher developed a treatment for hepatitis C. He set up a small firm to develop the drug further. After more progress was made a big biotech firm came along in 2011 and bought the startup for $11 billion. That buyer was Gilead. It priced its hepatitis C treatment, Sovaldi, at $84,000, allowing it to recoup most of the billions it spent buying the launch-ready drug by the end of the first year it went on sale. Sovaldi’s sky-high price, and Gilead’s pricing practices, subsequently became hot-button issues. Deploying the same argument it later used to defend remdesivir’s price, Gilead said Sovaldi’s rich price was warranted because the drug helped hospitals and patients spend less, overall, on treatments.Public Citizen has criticized Gilead for how it’s now pricing remdesivir, pointing out that it received $70 million in public funds to develop the drug. Gilead says it will have spent $1 billion developing and distributing remdesivir by the end of this year. A nonprofit group that assesses how drugs are priced, the Institute for Clinical and Economic Review, or ICER, said Gilead demonstrated “restraint” by setting a “responsible” price for remdesivir. As my Bloomberg Opinion colleague Max Nisen has already pointed out, advocating a rock-bottom price for remdesivir that merely allows it to recover development costs is unreasonable — and possibly misguided if it undermines further private-sector incentives to pursue innovative research.Still, the pharmaceutical industry has been stubbornly opaque about how much it truly spends developing drugs. It has successfully lobbied for years against regulations and revised accounting standards that might force it to be more transparent about how much all of its recipes cost.As STAT, a health-care news site, has observed, ICER had a very elastic grip of Gilead’s costs and pricing for remdesivir. If remdesivir doesn’t end up saving lives, ICER said the drug might be worth just $310. It also pointed out that to recoup its expenses developing the drug, Gilead could charge anywhere from $10 to $1,600 per patient — a huge range that doesn’t instill confidence about how well outsiders truly understand Gilead’s costs.And, again, that’s the core problem: There isn’t enough transparency in the pharmaceutical industry. Until the industry is far more open about its true costs, there’s no reason to take it at its word when it discusses expenses.Stonewalling critics might have worked in the past, when the importance of public health could be shunted aside or the threat of pandemics seemed less apparent. Now that Covid-19 has taught the world that some diseases are freighted with economic and national security threats and have the capacity to expose social injustices along the way, figuring out fair drug prices probably won’t be left to private companies, investors and captive regulators alone. A more muscular role for the federal government in drug development may lie ahead and Big Pharma may come to be seen and treated like a public utility — with all of the regulation and transparency that entails. Prices, in a post-pandemic world steeling itself against future pandemics, might not be set according to what the market will bear and what drug companies can get away with.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Timothy L. O'Brien is a senior columnist for Bloomberg Opinion.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 07/02/2020
|
Global health experts criticize U.S. deal to hog supply of coronavirus drug
- Public health experts on Wednesday criticized the U.S. for securing a large supply of the only drug licensed so far to treat COVID-19.
- 07/01/2020
|
WRAPUP 1-World takes stock of COVID-19 drug remdesivir after U.S. snaps up supplies
- Some governments in Europe and Asia said on Wednesday they have enough of Gilead's COVID-19 anti-viral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months. Remdesivir is in high demand after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial.
- 07/01/2020
|
Coronavirus update: U.S. case tally climbs above 2.6 million, and top Republicans now call on Americans to wear face masks
- The number of confirmed cases of the coronavirus illness COVID-19 in the U.S. climbed above 2.6 million on Wednesday, a day after Dr. Anthony Fauci said it could spike to more than 100,000 a day if the fresh clusters emerging in the South and West are not brought under control.
- 07/01/2020
|
EU in talks with Gilead to get remdesivir doses for EU countries
- The European Commission said on Wednesday it was in negotiations with Gilead Sciences Inc to obtain doses of COVID-19 antiviral remdesivir for the 27 European Union countries. The Commission said it took note of the announcement that the United States had secured nearly all of Gilead's projected production capacity for the next three months.
- 07/01/2020
|
Here’s the latest on what we know works — and doesn’t work — in treating coronavirus infections
- Steroids and Remdesivir have already been shown to help fight COVID-19. It’s too early to judge on a couple of other possibilities.
- 07/01/2020
|
UK emergency remdesivir supplies adequate to treat COVID-19, official says
- Britain has adequate supplies of Gilead's remdesivir for emergency use to treat hospitalised COVID-19 patients, England's deputy chief medical officer said on Wednesday, though he warned of potential difficulties securing future supplies. "I judge us to have adequate stocks," Jonathan Van-Tam, deputy chief medical officer and lead for the Department for Health and Social Care, told a parliamentary hearing.
- 07/01/2020
|
UPDATE: U.S. government to secure majority of Gilead's remdesivir supply through September
- Health officials said Monday that the U.S. government will receive 500,000 treatment courses of Gilead Sciences Inc.'s remdesivir through September that can then be purchased by American hospitals. This means that the U.S. will receive 100% of Gilead's total remdesivir production in July and 90% in August and September, a decision that has prompted criticism in Europe and the U.K. Gilead in May received an emergency use authorization from the Food and Drug Administration for remdesivir as a treatment for some severely ill, hospitalized COVID-19 patients. Gilead announced pricing for remdesivir earlier on Monday; the drug will cost $2,340 for a 5-day course of treatment in developed countries, with one exception. The cost of treatment for people who have commercial health insurance is $3,120. The Department of Health and Human Services said in a news release that AmerisourceBergen Corp. will continue to ship the drug. Following the EUA in early May, Gilead had donated more than 100,000 doses of remdesivir to the U.S. government, which then dispensed the drug to hospitals.
- 07/01/2020
|
Pfizer, BioNTech vaccine shows positive results: RPT
- Yahoo Finance’s Anjalee Khemlani joins The First Trade to break down the latest headline news about the coronavirus, including Pfizer’s recently released phase 1 data.
- 07/01/2020
|
Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual
- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that new data from the company’s HIV research and development program will be presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) from July 6-10. The breadth of data presented at the meeting, along with Gilead-led symposia and workshops, reflect the company’s commitment to advancing the scientific understanding of HIV prevention, treatment and cure strategies.
- 07/01/2020
|
Germany for now has enough remdesivir for COVID-19 therapy -govt
- Germany has for now secured enough supplies of remdesivir, which is set to become the first COVID-19 treatment approved in Europe, and is banking on developer Gilead to meet future needs, the country's health ministry said on Wednesday. With a conditional market approval, which is expected to be issued by the EU Commission this week, comes an obligation to deliver sufficient quantities in the future, it added.
- 07/01/2020
|
New South Wales Shuts Border; Fauci Issues Warning: Virus Update
- (Bloomberg) -- Anthony Fauci, the U.S. government’s top infectious disease specialist, warned lawmakers that coronavirus infections could rise to 100,000 a day if behaviors don’t change. Trump says in Twitter post that he’s ‘more and more angry at China’ over the pandemic. New South Wales, Australia’s most-populous state, said residents of 10 virus hotspots in neighboring Victoria would face six months in jail or a fine of A$11,000 if they attempt to cross the border. The Japanese government is considering starting talks with China, South Korea and Taiwan as soon as this month to ease travel restrictions imposed to prevent the spread of coronavirus, Asahi reports, citing unidentified government officials.Property markets in Singapore and Australia extended their downward trend amid the pandemic. Home prices in the city state fell for a second consecutive quarter after a two-month lockdown shut most of its economy, while Australian prices fell for a second straight month in June.Key Developments:Global Tracker: Cases Surpass 10.4 million; deaths top 508,000How do people catch Covid-19? What experts say: QuickTakeTrump’s Surgeon General Says ‘Please, Please, Please’ Wear MaskAirlines risk extinction as India refuses to rescue billionairesU.S. states beg, borrow and cut to close massive budget gapsReopened Los Angeles sleepwalks into resurgent pandemicSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus.South Korea Reports 51 New Cases; Starts to Use Remdesivir (09:18 a.m. HK)South Korea confirms 51 more cases Wednesday, bringing the total number of cases in the country to 12,850. The South Korean government will start supply of Remdesivir to local hospitals on July 1 after signing import contract with Gilead Sciences Korea, the nation’s Centers for Disease Control & Prevention said in an emailed statement. The use of the drug will be limited to patients in serious conditions, it added.Singapore, Australia Home Prices Fall as Shutdown Hits Property Market (09:04 a.m. HK)Singapore home prices fell for a second consecutive quarter after a two-month lockdown shut most of the economy and put the brakes on the real-estate market. Property values declined 1.1% in the three months ended June 30, according to a preliminary estimate from the Urban Redevelopment Authority released Wednesday. In the first quarter, prices dropped 1%.Australian house prices fell for a second straight month in June, as the coronavirus shutdowns continue to weigh on the property market. Home values in major cities fell 0.8% last month, accelerating from a 0.5% decline in May, according to CoreLogic Inc. data released Wednesday. The slide was led by Melbourne and Perth, where prices dropped 1.1%. In Sydney, prices fell 0.8%.Australian State Shuts Border to Virus Hotspot Residents (08:56 a.m. HK)New South Wales, Australia’s most-populous state, said residents of 10 virus hotspots in neighboring Victoria would face six months in jail or a fine of A$11,000 if they attempt to cross the border.The 10 areas of Melbourne go into lockdown shortly before midnight as authorities attempt to crush a spike in coronavirus infections. Victoria state has experienced two weeks of double-digit increases in new Covid-19 cases after social distancing restrictions were eased, jeopardizing its economic recovery and prompting other states to delay plans to open their borders.Mexico Cases Jump; Aeromexico Files for Chapter 11 (08:19 a.m. HK)Mexico reported 5,432 new confirmed Covid-19 cases, bringing the total 226,089, according to data released by the Health Ministry. Deaths rose 648 to 27,769.Grupo Aeromexico SAB, Mexico’s second-largest airline, said it filed for bankruptcy in the U.S., becoming the latest in a string of Latin American carriers to seek court protection after the Covid-19 pandemic caused a severe downturn in travel.The carrier will “continue operating and use Chapter 11 as a way to strengthen its financial position and liquidity,” according to a statement to the Mexican stock exchange Tuesday. Aeromexico said the goal will be “protecting and preserving its operations and assets and implementing the necessary operational adjustments to face Covid-19-related impact.”Virus-Hit Airlines Get UN Body to Ease Climate-Reduction Plan (08:15 a.m. HK)A U.N. body has eased a greenhouse gas reduction plan at the urging of the airline industry, which cited the coronavirus’ financial damage as an obstacle to achieving the plan’s intended targets.The Montreal-based International Civil Aviation Organization’s 36-nation council agreed to make 2019 the sole baseline year for the Carbon Offsetting and Reduction Scheme for International Aviation, or CORSIA, at a meeting on Tuesday.The program, which takes effect next year, originally included 2020 as a baseline. But the steep drop in airlines emissions this year when the coronavirus virtually halted some travel would mean airlines would have to offset more emissions under the program, creating an inappropriate economic burden, the organization said in a news release.Goldman Estimates 40% of U.S. Has Reversed or Halted Re-Opening (07:59 a.m. HK)More than 40% of the U.S. has now reversed or halted economic re-opening moves, after steps taken across the Sun Belt in recent days, according to estimates by Goldman Sachs Group Inc. economists. The bank also calculated that the share of the population in states where policies are getting more restrictive up to 30% over five days.“With case growth still accelerating nationwide, states are likely to continue to take further targeted measures to attempt to mitigate virus spread and maintain available healthcare capacity at sustainable levels,” Goldman analysts including Jan Hatzius, Alec Phillips and Blake Taylor wrote in a June 30 note.China Reports 3 New Coronavirus Cases June 30, All From Beijing (07:48 a.m. HK)China reported 3 new coronavirus cases Tuesday, and all of them are Beijing local cases, according to a statement from China’s National Health Commission. Three asymptomatic cases are reported and all of them are imported, the statement says, adding that China has 100 asymptomatic coronavirus cases under medical observation.Japan Eyes Easing China, S. Korea Travel Restrictions: Asahi (07:17 a.m. HK)The Japanese government is considering starting talks with China, South Korea and Taiwan as soon as this month to ease travel restrictions imposed to prevent the spread of coronavirus, Asahi reports, citing unidentified government officials.Japan plans to prioritize business travelers and then open borders to students, while tourists will be the last to be allowed entry, the report says.U.K. Bounceback Hopes Weakened as Firms See Record Sales Slump (07:01 a.m. HK)Hopes of a swift recovery for the U.K. economy could be dashed, according to a survey that revealed the parlous state of Britain’s businesses.Measures of sales, orders and cashflow in the nation’s dominant services sector have plunged by the most in the 31-year history of the British Chambers of Commerce’s quarterly survey. Demand for goods from manufacturers also dropped in the three months through June, with sentiment in the industry sliding to the weakest level since the financial crisis.The findings add weight to concerns the economy will struggle to rebound quickly from the pandemic.Trump Says He’s ‘More and More Angry at China’ Over Pandemic (06:56 a.m. HK)“As I watch the Pandemic spread its ugly face all across the world, including the tremendous damage it has done to the USA, I become more and more angry at China,” President Trump says in Twitter post.“People can see it, and I can feel it!”, Trump says.Iran to Lock Down Gulf Trade Hub (6:28 a.m. HK)Iran will reintroduce lockdown measures on one of its busiest port cities on the Persian Gulf following a surge in cases.Bandar Abbas, the capital of Hormuzgan province and a major trade hub on the Strait of Hormuz, is one of seven cities that will be closed for one week from Friday, Fereydoun Hemmati, the provincial governor told reporters, the semi-official Iranian Students’ News Agency reported.The islands of Kish and Qeshm, which are major tourist attractions, will also face the measures, Hemmati said, adding that the lockdown will involve the closure of all schools, universities, most offices, cinemas, coffee shops, restaurants, public pools, gyms and parks.Trump’s Task Force Boosts Call for Mask Use (6 a.m. HK)The Trump administration’s coronavirus task force stepped up its calls for Americans to wear masks, but Vice President Mike Pence said there were no plans to override governors who have yet to require them.“Please, please, please wear a face covering when you go out in public,” Surgeon General Jerome Adams, a member of the task force, said at a White House briefing Tuesday.Adams delivered the strongest plea to the public yet from an administration that has often sidestepped direct recommendations to wear masks. Health Secretary Alex Azar and Pence both urged wearing a mask at the same event Tuesday in Rockville, Maryland, though Pence only said to do so if local authorities recommended it.President Donald Trump has mocked his Democratic challenger Joe Biden for wearing a mask and has never publicly worn one, though he is facing calls to do so.U.S. Cases Rise by More Than 48,000 (4 p.m. NY)Coronavirus cases in the U.S. increased by 48,096 to 2.61 million as compared with the same time yesterday, according to data collected by Johns Hopkins University and Bloomberg News. The 1.9% gain was above the average daily increase of 1.6% over the past week. Deaths rose 0.5% to 126,512.Texas posted its worst day yet for new cases, with 6,975 positive tests that pushed to total to 159,986, according to state health department figures. The 4.
- 07/01/2020
|
Global Discrete Diode Market Analysis Highlights the Impact of COVID-19- 2020-2024 | Growing Adoption of Industry 4.0 Standards to Augment Growth | Technavio
- The Global Discrete Diode Market will grow by $ 431.64 million during 2020-2024
- 07/01/2020
|
Hedge Funds Dropped The Ball On Diodes Incorporated (DIOD)
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 06/30/2020
|
Low Voltage Automotive Buck Converter from Diodes Incorporated with Programmable PFM/PWM for Enhanced Efficiency
- Diodes Incorporated (NASDAQ: DIOD) today announced the AP61100Q, a 5.5V, 1A continuous output current, automotive-compliant, synchronous buck converter for point of load (POL) applications. With a fully integrated 110mΩ high-side power MOSFET and 80mΩ low-side power MOSFET, it provides high-efficiency step-down DC-DC conversion from 5V and 3.3V input rails. The converter has been developed for use in automotive applications including infotainment systems, instrumentation clusters, telematics, and advanced driver assistance systems (ADAS).
- 06/30/2020
|
Coronavirus update: Global COVID-19 case tally tops 10 million and Florida, South Carolina and Nevada set daily records
- The number of confirmed cases of the coronavirus illness COVID-19 topped 10 million around the world and the death toll surpassed a half million over the weekend, and Florida, South Carolina and Nevada all recorded their highest number of new infections in a single day.
- 06/30/2020
|
Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not
- Gilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pharmaceutical pricing of treatments and vaccines during the pandemic.
- 06/30/2020
|
PRESS DIGEST- New York Times business news - June 30
- - Reddit, one of the largest social networking and message board websites, on Monday banned its biggest community, The_Donald, devoted to U.S. President Donald Trump as part of an overhaul of its hate speech policies. - Uber Technologies Inc has made a takeover offer to buy Postmates Inc, the upstart delivery service, according to three people familiar with the matter, as the on-demand food delivery market consolidates and Uber looks for new ways to make money. - The administration of U.S. President Donald Trump placed new restrictions on U.S. exports of defense equipment and certain high-technology products to Hong Kong on Monday, in response to a new Chinese law aimed at tightening Beijing's control over the territory.
- 06/30/2020
|
Gilead Discloses Pricing Plans for Covid-19 Treatment Remdesivir. What It Means for the Stock.
- Gilead’s CEO said that a five-day course of remdesivir will cost private health insurers in the U.S. $3,120, and will cost governments of developed nations, including the U.S., $2,340.
- 06/29/2020
|
U.S. Cases Rise 1.2%; Worst Yet to Come, WHO Says: Virus Update
- (Bloomberg) -- New Jersey halted plans for indoor dining and New York City said it’s considering the same move as other U.S. states experience a surge in Covid-19 cases after reopening restaurants and bars. One of those states, Florida, reported a jump in its double-digit infection rate.Gilead Sciences Inc. said it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir, or about $2,340 for a typical five-day course of treatment.Deaths from the virus surpassed 500,000 worldwide and confirmed cases exceeded 10 million as the World Health Organization warned that the worst is yet to come. Tokyo reported more incidences of the disease, daily deaths in Iran reached a record and cases in Austria rose to the highest level since mid-May.Key Developments:Global Tracker: Cases pass 10.1 million; deaths top 502,500Swedish Covid expert says the world still doesn’t understandTrump dismisses virus, polls and recession to tell winning storyReviving Britain’s economy is tough with an aging workforceBoutique Manhattan hotel turns into Covid fortress to surviveOne big question: Are we going back into lockdown?: QuickTakeSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click VRUS on the terminal for news and data on the coronavirus.Texas Cases Rise 2.9% (4:45 p.m. NY)Texas posted a 2.9% increase in new cases, which pushed the cumulative total to 153,011, according to state health department figures. The one-day increase trailed the seven-day average of 4.2% and was the lowest in a week.In Houston, where emergency rooms and intensive-care units have been strained by the influx of patients, the cohort of Covid-19 patients in ICUs below the age of 40 is about 15%, David Persse, the city’s director of emergency medical services, said during a media briefing on Monday.“They are extremely ill,” Persse said. “If they’re thinking, ‘I’ll get sick and then I’ll get over it,’ recognize that 15% of the people in ICUs now are in their 20s and 30s.”Since late May, calls to the city’s 911 system have soared by almost 40%, driven by respiratory-distress cases, Fire Chief Samuel Pena said during the briefing. Emergency rooms are getting backed up trying to admit the influx of patients and that’s delaying how quickly ambulances can return to service and respond to new 911 calls, he said.Unions Sue Vegas Casinos Over Virus Protection (4:30 p.m. NY)MGM Resorts International’s Bellagio and Signature Condominiums, as well as Caesars Entertainment Corp.’s Harrah’s, were sued by Las Vegas labor unions for allegedly failing to do enough to protect workers from Covid-19.The culinary workers and the bartenders unions filed a complaint Monday in federal court in Las Vegas claiming the hotel and casino operators wouldn’t immediately close and deep-clean areas where infected employees had worked and would require employees to continue working without immediate informing them that a co-worker had tested positive or conducting contact tracing to see if they had been exposed.“Nothing is more important to us than the safety of everyone inside of our properties,” MGM Resorts said in response to the lawsuit. “We have spent months working with health experts to create a comprehensive health and safety plan. We have offered free testing to all employees before they report to work and require it if they exhibit symptoms or have been exposed to someone who has tested positive.”Representatives of Caesars didn’t immediately respond to a request for comment on the allegations.U.S. Cases Rise 1.2% (4 p.m. NY)Coronavirus cases in the U.S. rose by 29,182 as compared to the same time Sunday to 2.56 million, according to data collected by Johns Hopkins University and Bloomberg News. The 1.2% increase was below the average daily increase of 1.6% over the past week. Deaths rose 0.2% to 125,928.Montana cases rose by 6.5% to 919, according to the data from Johns Hopkins and Bloomberg News.Florida reported 146,341 cases, up 3.7% from a day earlier, compared with an average increase of 5.5% in the previous seven days. Deaths reached 3,447, an increase of 0.8%,California cases rose 2.5%, less than the seven-day average of 2.8%, for a total of 216,550. Deaths rose 0.5% to 5,905.AMC Delays Theater Reopenings to July 30 (3:30 p.m. NY)AMC Entertainment Holdings Inc., the largest U.S. cinema chain, will start reopening its theaters on July 30, two weeks later than expected, after Hollywood studios rescheduled nearly every movie that was supposed to come out next month.The chain said Monday it will reopen 450 locations on July 30, and a further 150 the following week. AMC initially planned a July 15 end to its four-month domestic closing, which was so devastating to the company that it warned it might go out of business. The first new big-budget film of the summer, “Tenet” from AT&T; Inc.’s Warner Bros., was expected to come out on July 17.NHL Says 26 Players Have Tested Positive (3:15 p.m. NY)The National Hockey League said 26 players have tested positive for coronavirus.As of Monday, 250 players have reported to training and practice facilities for optional participation in reopening activities, the NHL said in a statement.Fifteen returning players tested positive while the league is also aware of 11 other players that have tested positive.The NHL said this month that training camps for 24 teams resuming play will open on July 10.N.J. Pauses Indoor Dining Plan for July 2 (2:58 p.m. NY)Governor Phil Murphy said he would pause New Jersey’s plans to restart indoor dining on July 2, citing concerns about such a “sedentary” activity especially among “outlier” bars and restaurants not following social distancing.This “brings me no joy to do this, but we have no choice,” Murphy said.New Jersey indoor dining, with capacity caps and other restrictions, had been scheduled to restart on July 2, four days before New York City was to do so. But New York Mayor Bill de Blasio and New York Governor Andrew Cuomo on Monday said skyrocketing cases in the South and West have prompted them to consider postponing dining’s return. Cuomo also cited the failure of some New York City residents to practice social distancing.10,000 Iran Health-Care Workers Have Virus (2:45 p.m. NY)Some 10,000 Iranian health-care workers have contracted the coronavirus and least 64 have died fighting the pandemic, Iraj Harirchi, Iran’s deputy health minister, said on state TV.On Monday, Iran reported its highest daily death toll from Covid-19 at 162. The country has 10,670 fatalities from more than 225,000 confirmed cases.Houston-Area ICU Beds Are 95% Full (2:07 p.m. NY)Houston-area intensive-care unit wards were 95% full as of Sunday night, up from 93% on Saturday, according to data from the Texas Medical Center. Covid-19 patients occupied 34% of the beds, compared with 31% a day earlier.The number of Covid-19 patients requiring ICU admission is growing by an average of 3.5% a day, the center said on its website. The hospital systems that inform the medical center’s database have 64 regular ICU beds available and another 877 additional slots that could be made available to handle an overflow.Miami-Dade ICU Use Highest Since Early May (1:30 p.m. NY)Miami-Dade -- Florida’s most populous county -- reported 1,149 patients with Covid-19 admitted to hospitals as of Monday, an increase of 67 from a day earlier and the highest level since at least the first week of May.The number of Covid-19 patients in intensive-care unit beds rose to 236 from 224, according to a report from the county. The number of Covid-19 patients on ventilators reached 90, up from 84 a day earlier. Both of those numbers were also the highest since early May.Worst Yet to Come, WHO Chief Says (12:30 p.m. NY)Tomorrow marks six months since the World Health Organization became aware of the novel coronavirus, and the “worst is yet to come” given a lack of global solidarity, Tedros Adhanom Ghebreyesus, head of the World Health Organization, said at a briefing in Geneva.Some countries are experiencing a resurgence of cases and half the deaths are coming from the Americas, he said.“This virus can be suppressed and contained using the tools at hand,” and countries shouldn’t wait for a vaccine to deal with it, Tedros said, giving the examples of South Korea, Japan and Germany. “If any country is saying that contact-tracing is difficult, it is a lame excuse.”The WHO will send a team of researchers to China next week to study the virus’s origins, Tedros said.Europe to Extend Travel Ban for U.S. (12:30 p.m. NY)European Union governments are poised to extend a travel ban for U.S. residents for at least two weeks, according to a draft of a decision due to be formally adopted on Tuesday.The wording of the decision, seen by Bloomberg, signals that the ban disrupting both business and leisure travel across the Atlantic won’t be lifted until U.S. authorities control the spread of the coronavirus pandemic.California Cases Rise 2.5% (12:30 p.m. NY)California’s virus cases rose 2.5%, less than the seven-day average of 2.8%, for a total of 216,550 confirmed infections. Deaths climbed by 0.5% to 5,905. The rate of positive tests over the past 14 days was 5.5%, compared with 4.8% a week ago.Arizona Virus Cases Rise 0.8% (12 p.m. NY)The Arizona Department of Health Services reported 625 new cases on Monday, a 0.8% increase, bringing the total to 74,533.While it was the lowest case increase since May 31, the agency said the data didn’t include all new infections because one of its lab partners didn’t submit a report. That may also lead to a larger-than-expected increase on Tuesday, it said.The state reported no new deaths Monday, keeping the number at 1,588.Planet Fitness Falls on Virus Report (11:30 a.m. NY)Planet Fitness Inc. fell as much as 6.
- 06/29/2020
|
US STOCKS-Wall St ends higher on Boeing bump, stimulus eyed
- Wall Street stocks closed higher on Monday and the S&P; 500 was poised to clinch its biggest quarterly percentage gain since 1998 as investors hoped for a stimulus-backed economic rebound, while a surge in Boeing shares helped boost the blue-chip Dow. The planemaker's shares jumped more than 14% after a 737 MAX took off on Monday from a Seattle-area airport on the first day of certification flight testing with U.S. Federal Aviation Administration and company test pilots, a crucial moment in Boeing's worst-ever crisis. A spike in virus infections in Southern and Western states last week sent the S&P; 500 down nearly 3%, but the threat of a deeper-than-feared recession has led investors to expect more stimulus measures from the Federal Reserve or Congress.
- 06/29/2020
|
US STOCKS-Wall St gains on Boeing bump, remdesivir hopes
- Wall Street climbed on Monday and the S&P; 500 moved closer to clinching its biggest quarterly gain since 1998 as investors clung to hopes of a stimulus-backed economic rebound, while Boeing shares shot higher to help boost the blue-chip Dow. The planemaker's shares jumped 10.2% after a 737 MAX took off on Monday from a Seattle-area airport on the first day of certification flight testing with U.S. Federal Aviation Administration and company test pilots, a crucial moment in Boeing's worst-ever crisis. A spike in virus infections in Southern and Western states last week sent the S&P; 500 down nearly 3%, but the threat of a deeper-than-feared recession has led investors to expect more stimulus measures from the Federal Reserve or Congress.
- 06/29/2020
|
ER physician on Remdesivir COVID-19 treatment: 'I worry this will be a very expensive endeavor'
- Dr. Jeremy Faust, ER Physician at Brigham and Women’s Hospital in Boston & Harvard Medical School Instructor joins Zack Guzman to address how hospitals are handling the coronavirus crisis.
- 06/29/2020
|
Were Hedge Funds Right About Buying Gilead Sciences, Inc. (GILD)?
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]
- 06/29/2020
|
Gilead Sets a Good-Enough Bar With Covid-Treatment Price
- (Bloomberg Opinion) -- Pricing a new medicine aimed at taming a pandemic is one of the touchiest scenarios imaginable for a drug company. Set the price too high, and the world will assail you for price gouging. Too low, and you risk bleeding money and investors. No decision will ever make everyone happy, but Gilead Sciences Inc.'s price for its Covid-19 treatment remdesivir is a solid attempt.According to details released by Gilead on Monday morning, a five-day course of remdesivir will cost about $2,340 in developed nations, including U.S. plans administered by the government. Private insurers will pay a steeper $3,120 in America. Developing nations will pay significantly less after Gilead in May decided to let generic drugmakers make a cheaper version of remdesivir for low-income nations that could cost as little as $600 a course.The developed-world price will attract critics, and the price gap with generics will grate. However, it's substantially lower than what Gilead could charge. Not maximizing profit in a pandemic is a low standard, but it’s a good sign that the first drugmaker to the finish line cleared it. There's no set formula for pricing medicines; drugmakers often charge what they think will be most profitable in different markets. A pandemic throws the usual priorities into disarray. Any effective medicine is dramatically more valuable, given enormous demand, but that same demand creates an imperative to avoid pricing that makes the drug less accessible. Meanwhile, companies also have to pour extra resources into development and expanding supply. Gilead, for instance, may spend as much as $1 billion on remdesivir this year. So it’s a tricky balance.Some argue for a price that doesn't do much more than recoup input costs. Given the need to incentivize further rapid research on treatments, that's an unrealistic and arguably misguided expectation. The Institute for Clinical and Economic Review (ICER) — an independent group that does cost-effectiveness analysis on medicines — has suggested that a reasonable price range for a full course of remdesivir ranges from $4,580 to $5,080, well above where Gilead settled on.Gilead's pricing looks less generous, though, without a somewhat optimistic read of the data. ICER's base calculations don't account for broad use of the potentially life-saving steroid dexamethasone and assume that remdesivir prevents deaths, something that hasn't been conclusively proven. Without those assumptions, its estimated fair price drops significantly, to as little as $310. What’s more, though a Gilead study suggests five days of infusion may be as good as a longer course, some patients may get a full 10 days, increasing the effective price.In an open letter published Monday about the pricing decision, Gilead CEO Daniel O'Day wrote that the drug's ability to reduce hospital stays by four days equates to savings of $12,000 per patient in the U.S. By that analysis, which excludes any other benefits, the drug is priced well below its value and likely cost in a less fraught environment. The letter is pretty clearly an effort to anchor the debate in a way that flatters Gilead; America's wildly inflated hospital prices are perhaps not the best pricing benchmark.This is still the sort of analysis drugmakers routinely use to justify prices that leave ICER estimates in the dust. Gilead is clearly showing some degree of restraint, especially given that some analysts suggested a higher figure. The company may also have a limited window of peak sales. Demand is likely to fall off if a vaccine or better options arrive.There's no perfect price for medicine, especially right now. However, especially when you factor in the availability of generics in the parts of the world where the price is a bigger impediment to access, Gilead did a decent job of walking a difficult tight rope. The company set a bar that other drugmakers at least need to match, and hopefully will exceed. Anything less will be tough to justify. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 06/29/2020
|
Gilead Sets Pricing For Remdesivir Drug Candidate At $2,340 Per Patient
- Gilead Sciences Inc. (GILD) on Monday priced its experimental coronavirus drug candidate remdesivir at $2,340 per patient for a 5-day treatment in the U.S. and other developed countries.The price for governments of developed countries is $390 per vial based on the assumption that patients are expected to receive a 5-day treatment course using 6 vials of remdesivir. In the U.S., the same government price of $390 per vial will apply. The price for U.S. private insurance companies will be $520 per vial.“We discounted the price to a level that is affordable for developed countries with the lowest purchasing power… to remove the need for country by country negotiations on price,” Gilead chairman and CEO Daniel O’Day said in an open letter. “At the current price of $390 per vial, remdesivir is positioned to achieve the aim of providing immediate net savings for healthcare systems.”O’Day added that remdesivir’s pricing has been a “topic that has attracted more speculation than any other” since U.S. regulators approved its emergency use in some COVID-19 patients in May.Piper Sandler analyst Tyler Van Buren said that the remdesivir pricing for developed countries, is "perfectly reasonable" and within expectations considering that the “value of early discharge is $12,000 per the US government”. Van Buren maintained a Buy rating on the stock with a $90 price target (reflecting 19% upside potential).O’Day said that by the end of this year, investment on the development and manufacturing of remdesivir is expected to exceed $1 billion. The company seeks to to produce more than 2 million treatment courses of its experimental drug candidate remdesivir by the end of the year and many millions more in 2021, it said last week.Remdesivir is a viral RNA polymerase inhibitor which means that it interferes with the production of viral genetic material, preventing the virus from multiplying. The investigational antiviral therapy has received Emergency Use Authorization (EUA) by the FDA to treat COVID-19.Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS) so that the HHS and states can manage allocation to hospitals until the end of September. After this period, once supplies are less constrained, HHS will no longer manage allocation, the company said.In the developing world, where healthcare resources, infrastructure and economics are very different, Gilead has entered into agreements with generic manufacturers to deliver treatment at a substantially lower cost.Shares in Gilead rose about 1% to $75.24 in late morning U.S. trading boosting the year-to-date advance to about 23%.For now, Wall Street analysts remain sidelined on the stock. The Hold consensus is based on 13 Hold ratings and 4 Sell ratings versus 10 Buy ratings. The $79.95 average price target implies 6.5% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: AstraZeneca Strikes $127 Million Deal With Brazil For Covid-19 Vaccine Vaxart Explodes 96%- And Rallies After-Hours- On Covid-19 Deal LabCorp Launches Neutralizing Antibody Test For Covid-19 More recent articles from Smarter Analyst: * Online Shopping Trends Another Good Omen for Amazon; Analyst Raises Price Target * Is BlackBerry Stock a Buy Right Now? This Is What You Need To Know * Nike Stock Will Surge 15% From Current Levels, Says Analyst * 2 Beaten-Up Penny Stocks That Look Set for a Rebound
- 06/29/2020
|
Gilead prices COVID-19 drug Remdesivir at over $3,000 with insurance
- As the country begins to pullback on reopenings, U.S. coronavirus cases continue to surge. Yahoo Finance’s Anjalee Khemlani weighs in.
- 06/29/2020
|
US STOCKS-Wall St gains as investors pin hope on stimulus-powered rebound
- Wall Street's main indexes inched up on Monday following a sharp selloff last week, as investors clung to hopes of a stimulus-backed economic rebound even as coronavirus cases surged, while a jump in Boeing shares boosted the blue-chip Dow. The planemaker rose 7.3% after the Federal Aviation Administration confirmed on Sunday it had approved key certification test flights for the grounded 737 MAX that could begin as soon as Monday. "The market is taking a tremendous amount of comfort in the fact that as long as we contain the virus, the economy is going to recover very fast and you're going to see cyclical stocks start to rally again," said Thomas Hayes, managing member at Great Hill Capital LLC in New York.
- 06/29/2020
|
Gilead prices remdesivir at $2,340 for treatment in most of the developed world
- Shares of Gilead Sciences Inc. gained 1.1% in premarket trading on Monday after the drugmaker disclosed that remdesivir, its experimental COVID-19 treatment, will cost $2,340 for a course of treatment. The drug hasn't been approved by the Food and Drug Administration but received an emergency use authorization from the regulator in May. The price, however, is slightly higher for the privately insured population in the U.S., at $3,120 per course of treatment. "There is no playbook for how to price a new medicine in a pandemic," Gilead CEO Daniel O'Day said in a statement. The price of $2,340 applies to all developed countries, a decision aimed at removing "the need for country by country negotiations on price," O'Day said. Remdesivir has since been approved in Japan and has been recommended for approval in the European Union. The Institute for Clinical and Economic Review, an organization that studies cost-effectiveness in medicine, last week updated its price recommendation for remdesivir, to $2,520 to $2,800 for a course of treatment, if patients are also prescribed dexamethasone. U.K. researchers recently discovered that the commonly used steroid can reduce mortality in some severely ill COVID-19 patients. Studies have found that remdesivir can reduce the amount of time that patients are in the hospital, but no mortality benefit has been found in clinical research at this time. Shares of Gilead are up 14.7% year-to-date, while the S&P; 500 is down 6.8%.
- 06/29/2020
|
HHS: 500,000 courses of Gilead Sciences' remdesivir to be available for sale
- Health officials said Monday that it will receive 500,000 treatment courses of Gilead Sciences Inc.'s remdesivir through September that can then be purchased by U.S. hospitals. Gilead in May received an emergency use authorization from the Food and Drug Administration for remdesivir as a treatment for some severely ill, hospitalized COVID-19 patients. Gilead announced pricing for remdesivir earlier on Monday; the drug will cost $2,340 for a 5-day course of treatment in developed countries, with one exception. The cost of treatment for people who have commercial health insurance is $3,120. The Department of Health and Human Services said in a news release that AmerisourceBergen Corp. will continue to ship the drug. Following the EUA in early May, Gilead had donated more than 100,000 doses of remdesivir to the U.S. government, which then dispensed the drug to hospitals.
- 06/29/2020
|
Major indices open mixed amid a surge in coronavirus cases
- Mike Ryan, UBS Wealth Management Americas Chief Investment Officer, Yahoo Finance’s Brian Sozzi and Jared Blikre to discuss the latest market action.
- 06/29/2020
|
Covid Changed the Definition of Corporate Leadership. Meet Barron’s New Top CEOs.
- In a Conference Board survey, U.S. chiefs cited the possibility of a recession as their top concern for this year. In March, the global pandemic shut down entire industries overnight. None of this has been easy on CEOs—or the companies they manage.
- 06/29/2020
|
‘The second wave may be even worse because people may not follow the requirements’: Dr. Kass
- On Monday, Gilead Sciences announced that it would charge more than $2,340 for the use of its remdesivir per patient. Dr Dara Kass, Associate Professor of Emergency Medicine at Columbia University Medical Center, joins The First Trade to break down Gilead Sciences’ announcement, developments in the vaccine race, and reopenings in the U.S.
- 06/29/2020
|
JPMorgan Chase & Co. Sells 112,998 Shares of Diodes Incorporated (NASDAQ:DIOD)
- JPMorgan Chase & Co. lessened its holdings in shares of Diodes Incorporated (NASDAQ:DIOD) by 82.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,550 shares of the semiconductor company’s stock after selling 112,998 shares during the quarter. JPMorgan Chase & Co.’s holdings in […]
- 06/26/2020
|
Diodes (NASDAQ:DIOD) Rating Lowered to Sell at Zacks Investment Research
- Diodes (NASDAQ:DIOD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Diodes Incorporated is a leading manufacturer and supplier of high-quality discrete and analog semiconductor products, primarily to the communications, computing, industrial, consumer electronics and automotive markets. The […]
- 06/26/2020
|
Drug pricing review group raises recommended price for Gilead's remdesivir
|
India's Hetero prices experimental COVID-19 drug remdesivir at $71 per 100 mg vial
- India's Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at 5,400 rupees ($71) per 100-milligram vial, the drugmaker said on Wednesday, as it prepares to ship them to hospitals in the country. The privately held company said it would supply 20,000 vials of the drug. Fellow Indian drug firm Cipla Ltd had said on Tuesday that its own version of the antiviral drug remdesivir would be priced below 5,000 rupees.
- 06/24/2020
|
Gilead To Acquire Stake in Cancer Drug Developer Pionyr For $275 Million
- Gilead Sciences Inc. (GILD) announced on Tuesday that it will buy a 49.9% equity stake in Pionyr Immunotherapeutics Inc., for $275 million.Under the terms of the deal, Gilead has an exclusive option to purchase the remainder of Pionyr, a privately held company developing first-in-class cancer immunotherapies, for $315 million. In addition, Pionyr’s shareholders will be eligible to receive up to $1.47 billion in option exercise fees and future milestone payments.“Pionyr is pursuing promising, novel biology in the field of immuno-oncology,” said Gilead’s Chairman and CEO Daniel O’Day. “The agreement represents important progress as we continue to build out Gilead's presence in immuno-oncology with innovative and complementary approaches.”Pionyr’s investigational cancer drugs, PY314 and PY159, have demonstrated preclinical efficacy, suggesting potential in solid tumors in combination with established anti-PD(L)-1 agents. Pionyr plans to file investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) for both PY314 and PY159 in the third quarter of this year.As part of the purchase agreement Gilead will provide Pionyr with additional funding for the PY314 and PY159 clinical programs, as well as ongoing research and development programs.The announcement comes after Gilead said on Monday that it expects to produce more than 2 million treatment courses of its experimental coronavirus drug candidate remdesivir by the end of the year and many millions more in 2021.Shares in Gilead declined less than 1% to $75.20 in afternoon U.S. trading trimming the year-to-date advance to about 16%.Wall Street analysts remain sidelined on the stock. The Hold consensus is based on 13 Hold ratings and 4 Sell ratings versus 10 Buy ratings. The $79.95 average price target implies 6.8% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: Gilead Aims To Produce More Than 2 Million Remdesivir Courses By Year-End Indian Drugmakers Get Regulatory Nod For Generic Version Of Gilead’s Remdesivir 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed More recent articles from Smarter Analyst: * Canadian Cannabis Producer Aurora Cannabis Plans Job Cuts, Closure of 5 Plants * J&J; Fails To Overturn Baby Powder Verdict, Damages Cut To $2.12B * Mastercard Buys Finicity For $825 Million; Top Analyst Cuts Rating * Check Point Teams Up With Coursera For Cybersecurity Education Program
- 06/23/2020
|
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that for $275 million the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics Inc., a privately held company developing first-in-class cancer immunotherapies, and an exclusive option to purchase the remainder of Pionyr. Under the agreement, Pionyr’s shareholders may receive up to an additional $1.47 billion in option exercise fees and future milestone payments.
- 06/23/2020
|
India's Cipla to price remdesivir version for COVID-19 under $66
- Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said. Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees.
- 06/23/2020
|
Coronavirus Latest: Monday, June 22
- As new cases of coronavirus continue to rise in the United States, Pfizer and Gilead Sciences announce the latest developments in their trials and New York City begins its phase 2 of reopening. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
- 06/22/2020
|
NYU Pulmonologist: COVID-19 is ‘a virus not like any other we’ve seen’
- Pulmonologist at NYU Langone Medical Center and Independent Women's Forum Visiting Fellow Dr. Qanta Ahmed joins Yahoo Finance’s Zack Guzman to discuss the rise in coronavirus cases as the White House says it’s bracing for an autumn wave. "
- 06/22/2020
|
Gilead Aims To Produce More Than 2 Million Remdesivir Courses By Year-End
- Gilead Sciences Inc. (GILD) said it expects to produce more than 2 million treatment courses of its experimental coronavirus drug candidate remdesivir by the end of the year and many millions more in 2021.After getting the green light from the U.S. Food and Drug Administration (FDA), Gilead announced that it is planning to start Phase 1 trials of an inhaled version of remdesivir this week and begin studies in patients with COVID-19 in August.Remdesivir is an investigational antiviral virus candidate, which is currently given to patients intravenously through daily infusions in the hospital. An inhaled formulation would be given through a nebulizer, which Gilead said could potentially allow for easier use outside the hospital, at earlier stages of the disease.“That could have significant implications in helping to stem the tide of the pandemic,” Gilead CEO Daniel O'Day said in an open letter.O’Day added that the company is also exploring whether patient outcomes can be improved by combining remdesivir with other therapies to fight both aspects of the disease: an antiviral to target the virus itself and another therapy to tackle the inflammatory response.In addition, Gilead announced plans for a “next wave of studies” of remdesivir, which will include vulnerable patient populations, including a study in pregnant women.Remdesivir is a viral RNA polymerase inhibitor which means that it interferes with the production of viral genetic material, preventing the virus from multiplying. Gilead’s investigational antiviral therapy has received Emergency Use Authorization (EUA) by the FDA to treat COVID-19.Shares in Gilead declined 1.6% to $76.23 in midday U.S. trading trimming the year-to-date advance to about 17%.For now though, Wall Street analysts remain sidelined on the stock. The Hold consensus is based on 14 Hold ratings and 4 Sell ratings versus 10 Buy ratings. The $79.95 average price target implies a modest 4.7% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: Indian Drugmakers Get Regulatory Nod For Generic Version Of Gilead’s Remdesivir 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed What Would a Merger Mean for Gilead? Top Analyst Weighs In More recent articles from Smarter Analyst: * TripAdvisor Warns Of 'Materially Worse' Revenue Performance in Q2; Shares Drop 5% * Merck Wins Keytruda China Approval; Analyst Applauds ‘First-Mover Advantage’ * Evoke Pharma Pops 86% In Pre-Market On FDA Approval Of Gimoti Nasal Spray * Elon Musk: Tesla’s 7-Seat Model Y Production Now Set For ‘Early Q4’
- 06/22/2020
|
Coronavirus update: Trump fans controversy over testing as cases spike worldwide
- Trump sparked a new controversy by suggesting that testing more people for the coronavirus has contributed to the U.S. holding the top spot in the world for COVID-19 diagnoses.
- 06/22/2020
|
Gilead to Begin Phase 1 Trials of an Inhaled Version of Remdesivir
- Biotech said it will start Phase 1 trials of an inhaled version of remdesivir in August, but the market has been cool to the news for the potential Covid-19 treatment.
- 06/22/2020
|
What to Do with Gilead Sciences (GILD) Stock Right Now?
- HealthInvest Partners AB is the investment management company of HealthInvest Small & MicroCap Fund. HealthInvest Partners recently released its April month Investor Letter, a copy of which you can download here. HealthInvest Small & MicroCap Fund rose 9.1% in April, which was broadly in line with its benchmark index. You should check out HealthInvest Partners […]
- 06/22/2020
|
Gilead's stock falls as it announces clinical trial for inhaled remdesivir
- Shares of Gilead Sciences Inc. were down 1.2% in trading on Monday after the drugmaker said it plans to start Phase 1 clinical trials for an inhaled version of remdesivir, its treatment for severely ill COVID-19 patients. An intravenous version of the drug received an emergency use authorization from the Food and Drug Administration in May. The new study will first test this version of the investigational medication in healthy patients before moving on to COVID-19 patients. It is thought that an inhaled drug would be easier to administer outside of a hospital setting. "That could have significant implications in helping to stem the tide of the pandemic," CEO Daniel O'Day said in a letter on Monday. O'Day also said Gilead plans to test whether remdesivir can help patients before they become severely ill, in vulnerable patient populations like children and pregnant women, and in combination with other therapies, including Eli Lilly & Co. and Incyte Corp.'s Olumiant and Roche Holdings' Actemra. "We have been keen to explore how remdesivir might work when combined with anti-inflammatory agents, particularly in the most severely ill patients," he wrote. Gilead's stock is up 17.9% year-to-date, while the S&P; 500 is down 4.1%.
- 06/22/2020
|
Gilead to test inhaled version of remdesivir on COVID-19 patients in August
|
Indian Drugmakers Get Regulatory Nod For Generic Version Of Gilead’s Remdesivir
- India’s drug regulator granted Cipla Ltd. and Hetero Labs the approval to produce and sell a generic version of Gilead Sciences Inc.’s (GILD) coronavirus drug candidate remdesivir.The two Indian drugmakers have been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country. Hetero’s generic version of remdesivir will be marketed under the brand name Covifor in India, while Cipla’s generic version of remedisvir will be called Cipremi.“In the light of increasing COVID-19 cases in India, the approval of Covifor (remdesivir) can prove to be a game-changer given its positive clinical outcomes,” Hetero chairman Dr. B. Partha Saradhi Reddy said in a statement. “Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country. We are prepared for ensuring enough stocks required to cater to the present needs.”Remdesivir has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalized with severe symptoms of the disease. Covifor will be available in 100 milligram doses which will be administered intravenously in a hospital setting.Remdesivir is a viral RNA polymerase inhibitor which means that it interferes with the production of viral genetic material, preventing the virus from multiplying. Gilead’s investigational antiviral therapy has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19.Shares in Gilead rose 4.6% to $77.47 on Friday taking the year-to-date advance to 19%.Five-star analyst Hartaj Singh at Oppenheimer this month reiterated a Buy rating on the stock with a $90 price target, saying that investors are ascribing little value to Gilead's quality emerging pipeline, and that any sustained weakness into 2Q20 should be viewed as a buying opportunity.Singh added that Gilead’s $1 billion investment in remdesivir manufacturing, R&D; and sales and marketing efforts are potentially not reflected in 2Q/3Q20 consensus earnings estimates, which could potentially lead to earnings misses.For now though, the majority of Wall Street analysts remain sidelined on the stock. The Hold consensus is based on 14 Hold ratings and 4 Sell ratings versus 10 Buy ratings. The $79.95 average price target implies a mere 3% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks)Related News: Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed What Would a Merger Mean for Gilead? Top Analyst Weighs In More recent articles from Smarter Analyst: * American Airlines Plans To Raise $3.5B In New Financing; Top Analyst Sees Stock Upside Potential * Aurora Cannabis Leap Frogs Canopy Growth as a Better Investment * Afrezza Could Push MannKind Shares Higher, Says 5-Star Analyst * Shopify Teams Up With Blackberry On Canadian Covid-19 App
- 06/22/2020
|
Are Robust Financials Driving The Recent Rally In Diodes Incorporated's (NASDAQ:DIOD) Stock?
- Diodes (NASDAQ:DIOD) has had a great run on the share market with its stock up by a significant 48% over the last...
- 06/21/2020
|
India gives Hetero Labs approval to make Gilead's COVID-19 drug
- India's drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science's experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday. The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said. India's Cipla Ltd has also received approval from the Drug Controller General of India (DGCI) to manufacture and market the drug, according to a report https://bit.ly/2AVcs0y in Indian Express.
- 06/21/2020
|
Biotech Stocks Are Getting Ready to Run. How to Play It.
- Given the amount of attention paid to Covid-19 treatments and vaccines, it would be easy to assume that all of the good news was already reflected in biotech stocks. That’s not quite the case.
- 06/20/2020
|
Parametric Portfolio Associates LLC Has $5.91 Million Stock Holdings in Diodes Incorporated (NASDAQ:DIOD)
- Parametric Portfolio Associates LLC lessened its stake in Diodes Incorporated (NASDAQ:DIOD) by 5.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 145,403 shares of the semiconductor company’s stock after selling 8,299 shares during the quarter. Parametric Portfolio Associates LLC owned 0.28% of Diodes […]
- 06/20/2020
|
How to Play Biotech’s Next Big Runup
- Given the amount of attention paid to Covid-19 treatments and vaccines, it would be easy to assume that all of the good news was already reflected in biotech stocks. That’s not quite the case.
- 06/20/2020
|
Nkarta files for IPO
- Nkarta Inc. , a South San Francisco-based biopharmaceutical company, filed for its initial public offering on Friday. It plans to list under the ticker "NKTX" on the Nasdaq Global Market. The company is developing natural killer (NK)-based cell therapies that treat certain types of cancer, an approach similar to chimeric antigen receptors (CAR)-T therapies, of which two (Novartis' Kymriah and Gilead Sciences Inc.'s Yescarta) have received approval from the Food and Drug Administration. Nkarta, which has raised about $125 million in funding, according to Crunchbase, spent about $17 million on research and development last year and had a net loss of $21 million in 2019. Investors include RA Capital, New Enterprise Associates, and Novo Holdings, which is part of the Novo Nordisk Foundation. It plans to put one of its two lead candidates into clinical trials in the third quarter of 2021.
- 06/19/2020
|
What we do know — and don’t know — about the coronavirus at day 100 of the pandemic
- Scientists and infectious-disease experts are pushing hard to understand more about the novel coronavirus that causes COVID-19 and how to treat patients suffering from the sometimes deadly illness and prevent transmission.
- 06/18/2020
|
Taking Winnebago Options for a Ride
- Winnebago is up more than 300% since mid-March. It reports earnings on June 24. Aggressive investors can consider a “bull spread” that pays off if the stock surges on earnings.
- 06/18/2020
|
Coronavirus vaccine update: Wednesday, June 17
- On Wednesday, Gilead Sciences announced that it would soon begin enrolling volunteers for the next phase of its Remdesivir trial. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about Gilead Science’s trial on The Final Round.
- 06/17/2020
|
Gilead Sciences to study use of coronavirus drug in children
- Gilead Sciences Inc. said Wednesday it started a clinical trial of using its drug remdesivir to treat COVID-19 in pediatric patients. "While the novel coronavirus appears to disproportionally affect adults - especially the elderly and those with underlying health conditions - concerning reports have been documented of children and young adults being hospitalized with COVID-19 and related autoimmune symptoms," said Gilead Chief Medical Officer Merdad Parsey in a statement. The drug maker said it will begin enrolling about 50 pediatric patients for the study ranging from newborns to adolescents. On May 1, the Food and Drug Administration granted an emergency use authorization for remdesivir to treat COVID-19, and said this week that treatments recently touted by President Donald Trump could interfere with the drug's effectiveness.
- 06/17/2020
|
Gilead to enroll pediatric patients for late-stage remdesivir study
- Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderate-to-severe COVID-19 in a late-stage study testing its experimental drug, remdesivir. Gilead's remdesivir, which has been at the forefront in the fight against the virus and has been given emergency use authorization in some countries, could be helpful in some patients after data showed it could shorten the time taken to recover from the disease. The company is already running a late-stage study testing the drug in 6,000 patients with severe COVID-19.
- 06/17/2020
|
Javier Rodriguez Joins Gilead Sciences’ Board of Directors
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to the company’s Board of Directors. Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout the United States and internationally that strives to improve patients’ quality of life through clinical innovation and integrated, personalized care. From 2014 to 2019, he was the CEO of DaVita Kidney Care, the company’s business unit that treats patients with kidney failure and end-stage renal disease. Mr. Rodriguez has spent more than 20 years in various executive roles at DaVita, driving the company’s transformation for how kidney care is delivered. In addition, he currently serves as a member of the boards of directors of DaVita and the Denver Metro Chamber of Commerce.
- 06/16/2020
|
Celebrate Oxford Covid Drug News, But Not With Travel Stocks
- (Bloomberg Opinion) -- As Covid-19 cases and hospitalizations continue to rise in the U.S. and other parts of the world, Oxford University scientists provided a much-needed piece of good news Tuesday: A large, randomized trial in the U.K. that compared dexamethasone — a generic steroid — to standard treatment found that the drug cut the risk of death in severely ill patients.The result comes with caveats. Researchers have only disclosed a limited press release's worth of data at this point and should make haste to publish more details. Until then, some caution is warranted. But the fact that dexamethasone appears to show promise is encouraging and its sheer affordability could help it save lives. In fact, it’s already gained approval for use in treating Covid-19 by Britain’s National Health Service. As I wrote earlier this month, with the virus still raging and no assurance of a safe and effective vaccine arriving any time soon, effective treatments are going to be essential in managing the pandemic. The study found that dexamethasone cut deaths by one-third in patients on ventilators and by one-fifth in patients who only needed oxygen. Putting that number in context is essential. According to the researchers, that equates to one life saved for every eight ventilated patients treated, or for every 25 non-ventilated patients who require oxygen. The drug didn’t help patients who didn't need oxygen. That result makes sense; the medicine is an anti-inflammatory intended to rein in a potentially deadly overactive immune response to infection, an issue that's likely most pronounced in the sickest patients. Still, preventing death is an impressive outcome. Gilead Sciences Inc.'s remdesivir, already approved for emergency use in several countries, has only proven it can reduce time to recovery. The dexamethasone results also come from a comparison of more than 2,000 patients to a control arm of over 4,000 patients. Once researchers disclose more data, that should serve as the backbone of a data set more robust than the one used to justify remdesivir’s approval. Unlike remdesivir, dexamethasone is widely available and uncomplicated to manufacture. In comparison to other potentially useful anti-inflammatory drugs such as Roche Holding AG's Actemra, it's cheap. These same features formed part of the appeal of hydroxychloroquine, a commonly available malaria drug once hyped as a treatment. Unlike that medicine, which was pulled from the market in the U.S. in part due to results from another arm of the same U.K. trial, dexamethasone seems like it works.One saved life for every eight to twenty-five people treated may not seem like much. But there are thousands of people hospitalized around the world right now that could benefit from this medicine, and thousands more are likely to join them if current trends continue. This drug has a better chance than most to reach patients worldwide and could lead to many better outcomes in the months to come.Dexamethasone isn't going to stop the pandemic in its tracks, and it shouldn't substantially shift individual behavior or opinions about the severe risks involved in contracting Covid-19 or spreading it to others. It certainly shouldn’t underpin an investment thesis for travel stocks. That said, the trial is a step toward understanding the disease; if a decades-old steroid can prevent deaths, there are likely more benefits to reap from other anti-inflammatory drugs or combination therapies.Silver bullets rarely exist in the world of medicine. But small steps can have a large impact over time.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- 06/16/2020
|
Coronavirus update: Global case tally tops 8 million and states reopen businesses even as infections and hospitalizations rise
- The number of confirmed cases of the coronavirus illness COVID-19 globally climbed above 8 million on Tuesday, and the number of infections continued to rise in many parts of the U.S. even as officials continued their push to reopen and end lockdowns.
- 06/16/2020
|
U.K. trial sparks interest in dexamethasone’s potential as a treatment for severely ill COVID-19 patients
- A snapshot of data from a clinical trial in the U.K. testing a commonly prescribed steroid as a treatment for some severely ill COVID-19 patients reduced deaths among those patients, a finding that sent U.S. stocks soaring on Tuesday morning.
- 06/16/2020
|
Coronavirus update: Oxford study boosts treatment hopes, market as some states rethink reopening plans
- A study by the University of Oxford has yielded promising results for a generic steroid that can reduce the risk of death among hospitalized coronavirus patients.
- 06/16/2020
|
U.K. clinical trial finds steroid reduces death in some severely ill COVID-19 patients
- A commonly used steroid reduced deaths in hospitalized COVID-19 patients who were on ventilators or receiving oxygen support, according to a snapshot of data from a clinical trial in the United Kingdom. The randomized study, which is being conducted by the University of Oxford, is testing dexamethasone as part of a larger trial evaluating multiple potential treatments for COVID-19. About 2,100 patients received a low dose of dexamethasone for ten days; another 4,300 patients received the standard of care. Though the steroid reduced death in ventilated and oxygen-receiving patients, it did not benefit patients with COVID-19 who did not require respiratory support. The trial's steering committee had halted enrollment in the dexamethasone arm on March 8. Oxford researchers said in a news release that they plan to publish the full clinical details "as soon as possible." "Dexamethasone is the first drug to be shown to improve survival in COVID-19," Dr. Peter Horby, a chief investigator for the study, said in the news release. "The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment." In the U.S., Gilead Sciences Inc.'s remdesivir is one of the few treatments to have an emergency use authorization as a COVID-19 therapy. The Food and Drug Administration on Monday revoked emergency authorizations granted in March to hydroxychloroquine and chloroquine, two decades-old malaria drugs.
- 06/16/2020
|
Diodes Incorporated (NASDAQ:DIOD) Position Increased by Nuveen Asset Management LLC
- Nuveen Asset Management LLC raised its holdings in shares of Diodes Incorporated (NASDAQ:DIOD) by 87.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 584,446 shares of the semiconductor company’s stock after buying an additional 271,855 shares during the period. Nuveen Asset Management LLC owned […]
- 06/16/2020
|
FDA warns hydroxychloroquine could interfere with Gilead coronavirus drug
- The effectiveness of a Gilead Sciences Inc. emergency treatment for COVID-19 could be hampered by other drugs that have been associated with treating the disease, the Food and Drug Administration warned late Monday. The agency said that remdesivir, a drug made by Gilead that recently gained an emergency use authorization from the FDA, could be adversely affected if combined with the drugs chloroquine phosphate or hydroxychloroquine sulfate. The FDA said that the latter two drugs could reduce the effectiveness of the Gilead drug. Earlier Monday, the FDA revoked its emergency use authorization for hydroxychloroquine and chloroquine. Gilead shares rose 0.1% after hours, following a 1.1% rise to close the regular session at $73.97.
- 06/15/2020
|
FDA warns against combination of malaria drug and Gilead's remdesivir
|
Is Now Still a Good Time to Buy Gilead Sciences (GILD) Stock? Oppenheimer Says ‘Yes’
- After Gilead Sciences' (GILD) antiviral drug remdesivir was identified as a potential treatment for COVID-19 earlier in the year, investors sent the stock up by 30%. But sentiment has somewhat soured recently, with shares on a downtrend since the late April yearly peak.However, Oppenheimer analyst Hartaj Singh has no such concerns over Gilead’s long-term prospects, and tells investors, “We view any GILD weakness as a potential buying opportunity.”Singh identifies 3 possible reasons for the recent weakness. The first concerns a broader trend, as COVID-19’s impact has diminished, investors have shifted focus from the biotech sector to other industries. Secondly, Gilead has a “a tricky 2Q20 earnings report coming up,” one in which the full effect of the COVID-19 pandemic will be revealed.Lastly, the commercial opportunity for remdesivir has been questioned recently, as Wall Street has wondered about Gilead’s business model for the drug. Additionally, the drug’s development has also been a drain on resources which could be a factor heading into the quarterly statement. “Remdesivir investments might not be adequately reflected in 2Q/20 consensus leading to volatility into 2Q20 earnings,” said Singh.But what the skeptics appear to be missing by fixating solely on remdesivir, Singh says, is the pharma giant’s increasingly strong and diverse pipeline.The 5-star analyst said, “While sales/ earnings growth has started (per our upgrade thesis 01/19), we still see the Street ascribing little value to an emerging/quality pipeline. Launches for filgotinib in rheumatoid arthritis (2H20), ulcerative colitis (2021), magrolimab ('22) should buttress earlier stage data for HIV capsid (1H21), oral PD-1 (2020), nebulized remdesivir (2H20), etc,”Accordingly, Singh has an Outperform rating on GILD to go a with a $90 price target, which implies about 22% upside from current levels (To watch Singh’s track record, click here)The rest of Street has mixed views when considering Gilead’s prospects. Gilead's Hold consensus rating is based on 10 Buys, 14 Holds and 4 Sells. However, the bulls have the edge, as the average price target is $79.95 and implies possible upside of 9%. (See GILD stock analysis on TipRanks)
- 06/15/2020
|
Coronavirus update: US sees steady resurgence as FDA puts nail in coffin of hydroxychloroquine debate
- The coronavirus extended its grip across the world on Monday, as the FDA appeared to end the debate over a controversial drug.
- 06/15/2020
|
Coronavirus update: U.S. death toll tops 115,000 amid growing worry about uptick in cases in Florida, Texas among others
- The U.S. death toll from the coronavirus illness COVID-19 climbed above 115,000 on Monday, and the stock market tanked amid growing concerns about the uptick in cases in several states after their first efforts to reopen after lockdowns.
- 06/15/2020
|
Billions or trillions: The great coronavirus trade-off
- Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Andy Serwer discuss the cost of developing a COVID-19 vaccine in such a short time, and why that money is worthwhile.
- 06/15/2020
|
Lilly Is Testing Its Arthritis Drug as a Coronavirus Treatment
- The company said it is sponsoring a 400-patient randomized trial to confirm whether the drug Olumiant can moderate Covid symptoms.
- 06/15/2020
|
Dr Reddy’s Labs Signs Licensing Agreement For Gilead’s Remdesivir
- Dr Reddy's Laboratories Ltd. (RDY) announced that it has entered into a non-exclusive licensing agreement to manufacture and sell Gilead Sciences Inc.’s (GILD) coronavirus drug candidate remdesivir.The agreement grants Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug remdesivir, a potential treatment for COVID-19, in 127 countries including India. Financial terms of the agreement weren’t disclosed.As part of the pact, Gilead will provide technology transfer for the manufacturing of the potential drug. However, Dr. Reddy’s will be in charge of ramping up manufacturing and obtaining regulatory approval for the marketing of remdesivir in respective countries.Gilead’s investigational antiviral therapy has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat Covid-19.Shares in Gilead have dropped about 5% over the past week and were trading at $73.20 as of Friday’s close.Five-star analyst Hartaj Singh at Oppenheimer last week reiterated his Buy rating on the stock with a $90 price target (23% upside potential), saying that investors are ascribing little value to Gilead's quality emerging pipeline, and that any sustained weakness into 2Q20 should be viewed as a buying opportunity.Singh noted that although the stock has this year outperformed the broader market and its peer-group indices, the trend has reversed over the past month. He attributes three reasons for this: a rotation from biotech into other sectors, concerns around monetizing remdesivir's potential in COVID-19 and a tricky 2Q20 earnings report coming up in late July.The analyst added that Gilead’s $1 billion investment in remdesivir manufacturing, R&D; and sales and marketing efforts are potentially not reflected in 2Q/3Q20 consensus earnings estimates, which could potentially lead to earnings misses.So what does the Street consensus say? TipRanks data shows that the majority of 14 analysts have a Hold rating on the stock, while the rest is divided between 10 Buys and 4 Sells, adding up to a Hold consensus. The $79.95 average price target is less optimistic than Singh’s as it indicates 9% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: Israel Is Said To Be In Talks To Buy Moderna’s Covid-19 Vaccine Candidate 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed AstraZeneca Inks Europe Deal For 400M Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Walmart Partners With Shopify To Expand Its E-Commerce Marketplace * 3M Reveals May Sales Slipped 20% To $2.2B * Tesla’s China Car Registrations Jump In May; Stock Down In Pre-Market On Analysts’ Rating Cuts * Accenture To Snap Up Sentelis In Latest AI-Boosting Move
- 06/15/2020
|
Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients
- Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19. Scientists at Lilly believe that baricitinib could help suppress a potentially lethal immune response to COVID-19 called "cytokine storm" and reduce COVID-19's ability to reproduce in infected cells. Lilly could potentially obtain U.S. regulatory approval for the drug as soon as August, Patrik Jonsson, the president of Lilly Bio-Medicines, told Reuters in an interview.
- 06/15/2020
|
